Javed Butler
#82,665
Most Influential Person Now
Researcher
Javed Butler's AcademicInfluence.com Rankings
Javed Butlerengineering Degrees
Engineering
#1806
World Rank
#2583
Historical Rank
Biomedical Engineering
#39
World Rank
#39
Historical Rank
Electrical Engineering
#258
World Rank
#296
Historical Rank
Javed Butlercomputer-science Degrees
Computer Science
#2756
World Rank
#2884
Historical Rank
Information Management
#13
World Rank
#13
Historical Rank
Machine Learning
#200
World Rank
#203
Historical Rank
Artificial Intelligence
#341
World Rank
#348
Historical Rank
Download Badge
Engineering Computer Science
Javed Butler's Degrees
- PhD Biomedical Engineering Stanford University
- Masters Electrical Engineering Stanford University
- Bachelors Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Javed Butler Influential?
(Suggest an Edit or Addition)Javed Butler's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (9561)
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013) (5272)
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013) (3504)
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. (2021) (2883)
- Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association (2011) (2450)
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017) (2433)
- Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association (2013) (2088)
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017) (1845)
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
- The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014) (1566)
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017) (1330)
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) (1081)
- Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (2005) (966)
- Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. (2004) (888)
- The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. (2009) (833)
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020) (599)
- Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. (2018) (580)
- The prognostic importance of different definitions of worsening renal function in congestive heart failure. (2002) (556)
- Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (2020) (512)
- Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. (2004) (491)
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. (2021) (468)
- Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. (2009) (435)
- Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. (2014) (422)
- Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. (2013) (417)
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure (2021) (395)
- Coronary Multidetector Computed Tomography in the Assessment of Patients With Acute Chest Pain (2006) (389)
- Endothelial dysfunction, arterial stiffness, and heart failure. (2012) (381)
- Mitochondrial function as a therapeutic target in heart failure (2016) (371)
- Prognostic importance of emotional support for elderly patients hospitalized with heart failure. (1998) (369)
- Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. (2010) (368)
- Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. (2019) (357)
- Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. (2007) (336)
- Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial (2016) (324)
- Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. (2007) (322)
- Developing therapies for heart failure with preserved ejection fraction: current state and future directions. (2014) (317)
- Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. (2018) (315)
- The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. (2004) (311)
- Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial (2017) (293)
- Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. (2014) (285)
- Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. (2015) (285)
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial (2020) (280)
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action (2017) (276)
- Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. (2015) (272)
- Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. (2011) (271)
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. (2015) (264)
- Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. (2021) (263)
- Risk factors for heart failure in the elderly: a prospective community-based study. (1999) (262)
- Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study (2017) (251)
- Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. (2019) (246)
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (2018) (229)
- Pulmonary hypertension and exercise intolerance in patients with heart failure. (1999) (219)
- Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging (2016) (212)
- Effect of a heart failure program on hospitalization frequency and exercise tolerance. (1997) (210)
- Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score (2008) (207)
- Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. (2016) (206)
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial (2018) (201)
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2022) (201)
- The vulnerable phase after hospitalization for heart failure (2015) (200)
- Metabolic syndrome and the risk of cardiovascular disease in older adults. (2006) (196)
- Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. (2013) (189)
- Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. (2009) (186)
- Reframing the association and significance of co‐morbidities in heart failure (2016) (181)
- Mode of Death in Heart Failure With Preserved Ejection Fraction. (2017) (178)
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial (2019) (175)
- Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage (2015) (175)
- 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. (2019) (173)
- The continuous heart failure spectrum: moving beyond an ejection fraction classification. (2019) (170)
- Outpatient adherence to beta-blocker therapy after acute myocardial infarction. (2002) (168)
- Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study (2015) (166)
- Comprehensive assessment of myocardial perfusion defects, regional wall motion, and left ventricular function by using 64-section multidetector CT. (2008) (166)
- Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured population (2010) (163)
- Association of major and minor ECG abnormalities with coronary heart disease events. (2012) (161)
- Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial (2017) (161)
- Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. (2010) (159)
- Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement From the American Heart Association/American Stroke Association (2016) (156)
- Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction. (2016) (156)
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020) (150)
- Utility of the Seattle Heart Failure Model in patients with advanced heart failure. (2009) (147)
- Frailty and risk for heart failure in older adults: the health, aging, and body composition study. (2013) (145)
- Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome (2017) (144)
- The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors (2017) (144)
- Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. (2006) (143)
- Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. (2015) (137)
- Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic (2020) (137)
- Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. (2017) (135)
- Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). (2014) (132)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. (2017) (132)
- Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. (2005) (130)
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial (2019) (129)
- Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) (2014) (125)
- Relationship between renal function and left ventricular assist device use. (2006) (125)
- Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial (2013) (124)
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review (2018) (124)
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. (2020) (120)
- Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score (2019) (120)
- Utility of Patient-Reported Outcome Instruments in Heart Failure. (2016) (118)
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction (2013) (118)
- Soluble guanylate cyclase: a potential therapeutic target for heart failure (2013) (118)
- Heart Failure in Patients With Human Immunodeficiency Virus Infection: Epidemiology, Pathophysiology, Treatment, and Future Research (2014) (117)
- Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. (2019) (116)
- Patient selection in heart failure with preserved ejection fraction clinical trials. (2015) (114)
- Incident Heart Failure Prediction in the ElderlyCLINICAL PERSPECTIVE (2008) (112)
- Adrenomedullin in heart failure: pathophysiology and therapeutic application (2018) (112)
- Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. (2017) (112)
- Therapeutic targets in heart failure: refocusing on the myocardial interstitium. (2014) (111)
- Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience (2020) (111)
- Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions (2016) (111)
- Dietary Sodium Intake in Heart Failure (2012) (109)
- Epidemiology and cost of advanced heart failure. (2011) (109)
- Heart failure with reduced ejection fraction (2017) (107)
- Serum albumin concentration and heart failure risk The Health, Aging, and Body Composition Study. (2010) (107)
- Left Atrium in Heart Failure With Preserved Ejection Fraction: Structure, Function, and Significance (2014) (105)
- Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study (2011) (103)
- Beta-blocker use and outcomes among hospitalized heart failure patients. (2006) (102)
- Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. (2016) (102)
- Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. (2019) (101)
- Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. (2009) (101)
- Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. (2019) (100)
- Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. (2012) (100)
- Racial disparities in health literacy and access to care among patients with heart failure. (2011) (99)
- Diabetes, Inflammation, and Functional Decline in Older Adults (2006) (98)
- Selection of patients for heart transplantation in the current era of heart failure therapy. (2004) (98)
- Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020) (98)
- Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. (2010) (98)
- Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. (2016) (97)
- Empagliflozin in Heart Failure (2020) (97)
- Framingham Risk Score and Alternatives for Prediction of Coronary Heart Disease in Older Adults (2012) (96)
- Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. (2014) (95)
- Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. (2015) (93)
- The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. (2014) (92)
- Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. (2019) (92)
- Coenzyme Q10 and Heart Failure: A State-of-the-Art Review (2016) (91)
- Hyperkalemia in Heart Failure. (2016) (90)
- Cardiorespiratory fitness and risk of heart failure: a population‐based follow‐up study (2014) (89)
- Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology (2020) (89)
- Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic (2020) (88)
- Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF) (2017) (88)
- Advance directives among hospitalized patients with heart failure. (2015) (88)
- The Importance of NLRP3 Inflammasome in Heart Failure. (2015) (88)
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function (2020) (87)
- Cigarette smoking exposure and heart failure risk in older adults: the Health, Aging, and Body Composition Study. (2012) (86)
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. (2018) (86)
- Global left atrial failure in heart failure (2016) (84)
- Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use (2015) (84)
- Association Between Cardiovascular Risk Profiles and the Presence and Extent of Different Types of Coronary Atherosclerotic Plaque as Detected by Multidetector Computed Tomography (2008) (83)
- Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. (2018) (83)
- Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. (2016) (83)
- Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial (2021) (83)
- Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. (2010) (82)
- Serum Resistin Concentrations and Risk of New Onset Heart Failure in Older Persons: The Health, Aging, and Body Composition (Health ABC) Study (2009) (82)
- The Cardioprotective Actions of Hydrogen Sulfide in Acute Myocardial Infarction and Heart Failure (2014) (81)
- Patient-reported selective adherence to heart failure self-care recommendations: a prospective cohort study: the Atlanta Cardiomyopathy Consortium. (2013) (80)
- Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: Results from the PET (Positron Emission Tomography) Prognosis Multicenter Registry. (2013) (80)
- Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. (2003) (79)
- Assessment of Right Ventricular Function in Left Ventricular Assist Device Candidates (2014) (79)
- Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial (2012) (78)
- The disconnect between phase II and phase III trials of drugs for heart failure (2013) (77)
- Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspective, Mechanisms, and Future Directions (2011) (77)
- Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. (2020) (76)
- Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. (2021) (76)
- The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. (2013) (75)
- Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). (2015) (75)
- Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The EXACT-HF Study (2015) (75)
- Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study (2017) (75)
- The QT interval and risk of incident atrial fibrillation. (2013) (74)
- N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. (2020) (74)
- Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure (2015) (73)
- Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat! (2008) (72)
- Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study (2018) (72)
- Concomitant diabetes mellitus and heart failure. (2015) (71)
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (71)
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. (2021) (71)
- Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. (2015) (70)
- Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial (2020) (70)
- Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review (2016) (69)
- Population Risk Prediction Models for Incident Heart Failure: A Systematic Review (2015) (69)
- Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. (2020) (69)
- Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study (2011) (69)
- Multidetector Computed Tomography for the Detection of Left Atrial Appendage Thrombus: A Comparative Study With Transesophageal Echocardiography (2007) (68)
- Right ventricular function with standard and speckle-tracking echocardiography and clinical events in adults with D-transposition of the great arteries post atrial switch. (2012) (66)
- Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE‐HF) (2018) (66)
- Hospital strategies to reduce heart failure readmissions: where is the evidence? (2012) (66)
- Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction (2018) (65)
- Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy (2019) (65)
- Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. (2019) (65)
- Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. (2021) (64)
- Acute decompensated heart failure: update on new and emerging evidence and directions for future research. (2013) (64)
- Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. (2017) (63)
- Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge (2004) (63)
- Validation of the Health ABC Heart Failure Model for Incident Heart Failure Risk Prediction: The Cardiovascular Health Study (2010) (62)
- Predictors of Incident Heart Failure in a Large Insured Population: A One Million Person-Year Follow-Up Study (2010) (62)
- Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. (2017) (62)
- The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. (2004) (62)
- Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. (2013) (61)
- Weight loss, malnutrition, and cachexia in COVID‐19: facts and numbers (2020) (61)
- Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. (2014) (61)
- Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure (2013) (61)
- Nitrite Therapy Improves Left Ventricular Function During Heart Failure via Restoration of Nitric Oxide–Mediated Cytoprotective Signaling (2014) (60)
- Comparison of multidetector computed tomography and two-dimensional transthoracic echocardiography for left ventricular assessment in patients with heart failure. (2007) (60)
- Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. (2015) (59)
- Developing New Treatments for Heart Failure: Focus on the Heart (2016) (59)
- Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure (2018) (59)
- Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes (2019) (59)
- Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. (2014) (59)
- Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. (2021) (58)
- Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs (2020) (58)
- Body Mass Index and Outcomes After Left Ventricular Assist Device Placement (2005) (58)
- Trends in 30- and 90-Day Readmission Rates for Heart Failure (2021) (58)
- Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction (2020) (57)
- In‐hospital worsening heart failure (2015) (57)
- Body mass index and outcomes after left ventricular assist device placement. (2004) (57)
- Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). (2014) (57)
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction (2021) (57)
- Frequency of low-risk hospital admissions for heart failure. (1998) (57)
- Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. (2012) (56)
- Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions (2014) (56)
- Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
- Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. (2020) (56)
- High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. (2014) (56)
- The immunological axis in heart failure: importance of the leukocyte differential (2013) (55)
- Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). (2014) (55)
- From risk factors to structural heart disease: the role of inflammation. (2012) (54)
- Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure (2015) (54)
- Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial (2019) (54)
- Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
- Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. (2015) (52)
- 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). (2020) (52)
- Digoxin Therapy Does Not Improve Outcomes in Patients With Advanced Heart Failure on Contemporary Medical Therapy (2009) (52)
- Left-ventricular systolic and diastolic dyssynchrony as assessed by multi-harmonic phase analysis of gated SPECT myocardial perfusion imaging in patients with end-stage renal disease and normal LVEF (2011) (52)
- Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis (2020) (52)
- A propensity-matched study of the association of cardiothoracic ratio with morbidity and mortality in chronic heart failure. (2008) (52)
- Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges (2018) (52)
- "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. (2015) (51)
- Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta‐Analysis (2015) (51)
- Length of hospital stay and 30‐day readmission following heart failure hospitalization: insights from the EVEREST trial (2015) (51)
- Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis (2017) (51)
- Empagliflozin and Major Renal Outcomes in Heart Failure. (2021) (50)
- Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. (2009) (50)
- Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. (2016) (50)
- The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial (2022) (49)
- The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study (2011) (49)
- Lung function and risk for heart failure among older adults: the Health ABC Study. (2011) (49)
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis (2020) (49)
- Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. (2019) (49)
- Increased mortality with elevated plasma endothelin‐1 in acute heart failure: an ASCEND‐HF biomarker substudy (2016) (49)
- Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. (2020) (48)
- Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics (2017) (48)
- Feasibility and optimization of aortic valve planimetry with MDCT. (2007) (48)
- Left Ventricular Dysfunction With Pulmonary Hypertension: Part 1 Epidemiology, Pathophysiology, and Definitions (2013) (48)
- Kidney Function and Outcomes in Patients Hospitalized with Heart Failure. (2021) (48)
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. (2018) (48)
- Influence of race/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients. (2013) (48)
- Depression in heart failure: Can PHQ-9 help? (2016) (48)
- Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. (2015) (47)
- A pilot test of an integrated self-care intervention for persons with heart failure and concomitant diabetes. (2014) (47)
- Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). (2010) (47)
- Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. (2013) (47)
- Extent and distribution of coronary artery disease: a comparative study of invasive versus noninvasive angiography with computed angiography. (2007) (47)
- Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic CardiomyopathyNovelty and Significance (2017) (47)
- Tolerability to beta-blocker therapy among heart failure patients in clinical practice. (2003) (47)
- Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. (2013) (47)
- Molecular and Cellular Basis of Viable Dysfunctional Myocardium (2014) (47)
- Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. (2016) (46)
- Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes (2014) (46)
- Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. (2013) (46)
- Hemoconcentration-guided diuresis in heart failure. (2014) (46)
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes. (2021) (45)
- Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. (2016) (45)
- Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. (2016) (45)
- Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction (2016) (45)
- Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics (2017) (45)
- Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? (2020) (45)
- Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. (2012) (45)
- Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure With Preserved Ejection Fraction: A Study-Level Pooled Analysis. (2018) (45)
- Management of comorbid diabetes mellitus and worsening heart failure. (2014) (44)
- Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. (2009) (44)
- Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. (2019) (44)
- Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. (2015) (44)
- Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial (2016) (44)
- Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. (2017) (44)
- Strategies and opportunities for drug development in heart failure. (2013) (43)
- Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. (2021) (43)
- Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition) (2017) (43)
- Trends in prevalence of comorbidities in heart failure clinical trials (2020) (43)
- Redefining Heart Failure With a Reduced Ejection Fraction. (2019) (43)
- Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives (2016) (42)
- Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. (2016) (42)
- Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. (2020) (42)
- Postmarketing Adverse Events Related to the CardioMEMS HF System (2017) (41)
- Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. (2021) (41)
- Echocardiographic evaluation of left ventricular structure and function: new modalities and potential applications in clinical trials. (2012) (41)
- Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND‐HF (2016) (41)
- Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. (2019) (41)
- Addressing the challenges of cardiorenal syndrome. (2006) (41)
- Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. (2020) (40)
- Myocardial Damage Detected by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Is Associated With Subsequent Hospitalization for Heart Failure (2013) (40)
- Change the management of patients with heart failure: Rationale and design of the CHAMP‐HF registry (2017) (40)
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
- Prevention, diagnosis, and treatment of hypertensive heart disease. (2010) (39)
- Cardiovascular implications of COVID-19 versus influenza infection: a review (2020) (39)
- Improved compliance with quality measures at hospital discharge with a computerized physician order entry system. (2006) (39)
- Atrial Fibrillation and Declining Physical Performance in Older Adults: The Health, Aging, and Body Composition Study (2016) (39)
- Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). (2015) (39)
- Depression in Patients with Cardiovascular Disease (2012) (38)
- Research Paper: Integrating "Best of Care" Protocols into Clinicians' Workflow via Care Provider Order Entry: Impact on Quality-of-Care Indicators for Acute Myocardial Infarction (2006) (38)
- Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction (2016) (38)
- Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial (2021) (38)
- Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials (2020) (38)
- Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM‐HF, INOVATE‐HF, and NECTAR‐HF (2020) (38)
- Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. (2015) (38)
- Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure (2019) (38)
- Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. (2014) (38)
- Modeling the effects of functional performance and post-transplant comorbidities on health-related quality of life after heart transplantation. (2003) (38)
- Risk for Incident Heart Failure: A Subject‐Level Meta‐Analysis From the Heart “OMics” in AGEing (HOMAGE) Study (2017) (38)
- Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis (2017) (38)
- Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. (2021) (37)
- Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. (2020) (37)
- Limitations of risk score models in patients with acute chest pain. (2009) (37)
- Leadership Gender Disparity Within Research-Intensive Medical Schools: A Transcontinental Thematic Analysis. (2019) (37)
- Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. (2019) (37)
- Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. (2016) (36)
- Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. (2019) (36)
- Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable: First Results From Get With The Guidelines–Atrial Fibrillation (GWTG-AFIB) (2019) (36)
- Heart Failure 2012 (2012) (36)
- Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure (2017) (36)
- Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults: Health, Aging, and Body Composition (Health ABC) Study (2013) (36)
- Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. (2016) (35)
- Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction (2013) (35)
- Echocardiographic Assessment of Pulmonary Artery Systolic Pressure and Outcomes in Ambulatory Heart Failure Patients (2014) (35)
- Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Findings From the EVEREST Trial (2014) (35)
- Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. (2015) (35)
- Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. (2009) (34)
- Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. (2008) (34)
- The Cardio-Renal Interrelationship. (2017) (34)
- Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. (2020) (34)
- Analysis of cardiac dimensions, mass and function in heart transplant recipients using 64-slice multi-detector computed tomography. (2007) (34)
- Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect (2016) (34)
- Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
- Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States (2018) (33)
- Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. (2019) (33)
- Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. (2013) (33)
- The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND‐HF (2016) (33)
- Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection (2018) (33)
- Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure (2016) (33)
- Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. (2020) (33)
- Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure (2020) (32)
- Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis (2019) (32)
- Natriuretic peptide-guided management in heart failure (2016) (32)
- Predictors of Incident Heart Failure in a Large Insured PopulationClinical Perspective (2010) (32)
- Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography (2010) (32)
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. (2021) (32)
- Effects of Elamipretide on Left Ventricular Function in Patients with Heart Failure with Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. (2020) (32)
- Relation of Living in a "Food Desert" to Recurrent Hospitalizations in Patients With Heart Failure. (2019) (32)
- Patient perception versus medical record entry of health-related conditions among patients with heart failure. (2011) (31)
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. (2019) (31)
- Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence (2016) (31)
- Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. (2020) (31)
- Water and Sodium in Heart Failure: A Spotlight on Congestion (2014) (31)
- Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. (2015) (31)
- Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. (2017) (30)
- Renal dysfunction in heart failure. (2012) (30)
- Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction (2021) (30)
- Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. (2019) (30)
- Prognostic significance of (123)I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. (2016) (30)
- Effect of age on outcomes after left ventricular assist device placement. (2006) (30)
- Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. (2021) (30)
- Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction (2015) (30)
- Effect of Short Call Admission on Length of Stay and Quality of Care for Acute Decompensated Heart Failure (2008) (30)
- Endpoints in Heart Failure Drug Development: History and Future. (2020) (29)
- Anticoagulation in heart failure: current status and future direction (2013) (29)
- Pre‐discharge and early post‐discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial (2018) (29)
- 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) (2021) (29)
- Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. (2016) (29)
- Lessons learned in acute heart failure (2018) (29)
- Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers (2020) (29)
- Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. (2009) (29)
- Diabetes and outcomes after left ventricular assist device placement. (2005) (29)
- Race and ethnic differences in the epidemiology and risk factors for graft failure after heart transplantation. (2015) (29)
- Association of Physical Activity or Fitness With Incident Heart Failure: A Systematic Review and Meta-Analysis. (2015) (29)
- Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study (2020) (28)
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. (2020) (28)
- Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. (2016) (28)
- Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns within an Academic Medical Center. (2020) (28)
- Clinical adoption of prognostic biomarkers: the case for heart failure. (2012) (28)
- Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. (2015) (28)
- Prostaglandin production contributes to exercise-induced vasodilation in heart failure. (1997) (27)
- Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. (2018) (27)
- Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (2021) (27)
- Analytic approaches to establish the diagnostic accuracy of coronary computed tomography angiography as a tool for clinical decision making. (2007) (27)
- Hospital certification for optimizing cardiovascular disease and stroke quality of care and outcomes. (2010) (27)
- Trends in characteristics of cardiovascular clinical trials 2001-2012. (2015) (27)
- Echocardiography in Acute Heart Failure: Current Perspectives. (2016) (27)
- Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations (2013) (27)
- Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results (2020) (27)
- Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry (2016) (27)
- Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. (2018) (27)
- Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure (2016) (27)
- The Sympathetic Nervous System in Heart Failure (2009) (27)
- Renal function in advanced heart failure. (2011) (26)
- Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. (2015) (26)
- Survival and quality of life after organ transplantation in veterans and nonveterans. (2003) (26)
- Left Ventricular Dysfunction With Pulmonary Hypertension: Part 2: Prognosis, Noninvasive Evaluation, Treatment, and Future Research (2013) (26)
- The bumpy road to drug development for acute heart failure (2016) (26)
- Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial (2018) (26)
- The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer. (2014) (26)
- Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. (2019) (26)
- A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. (2017) (26)
- Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure (2018) (26)
- Coronary Computed Tomography Angiography for Early Triage of Patients With Acute Chest Pain (2009) (25)
- Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. (2021) (25)
- Primary Prevention of Heart Failure (2012) (25)
- Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. (2020) (25)
- Trends in Heart Failure Clinical Trials From 2001-2012. (2016) (25)
- Cardiomyopathy and Heart Failure in Patients With HIV Infection. (2019) (25)
- The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers (2013) (25)
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial (2022) (25)
- Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions (2018) (25)
- Rationale and Design of the VITALITY-HFpEF Trial. (2019) (25)
- Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial (2020) (25)
- Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event (2020) (25)
- High‐density lipoprotein‐associated paraoxonase‐1 activity for prediction of adverse outcomes in outpatients with chronic heart failure (2017) (24)
- Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. (2015) (24)
- The Right Ventricular Function After Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. (2016) (24)
- The cardiorenal syndrome in heart failure: cardiac? renal? syndrome? (2012) (24)
- Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. (2018) (24)
- Relation of the metabolic syndrome to quantity of coronary atherosclerotic plaque. (2008) (24)
- Aspirin use for the primary prevention of coronary heart disease in older adults. (2005) (24)
- Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology (2022) (24)
- In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. (2021) (24)
- Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF (2018) (24)
- Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities (2020) (24)
- Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1‐receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction (2018) (24)
- Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. (2017) (23)
- Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme (2022) (23)
- Effect of Empagliflozin on Cardiovascular and Kidney Outcomes in Patients with Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial (2021) (23)
- Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial (2021) (23)
- A perspective on re‐evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile (2014) (23)
- Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks: The Jackson Heart Study (2018) (23)
- Multidrug-Resistant Organism Infections in Patients with Left Ventricular Assist Devices. (2015) (23)
- High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network (2018) (23)
- Six‐minute walk distance predicts 30‐day readmission after acute heart failure hospitalization (2017) (23)
- Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? (2016) (23)
- SPECT and PET in ischemic heart failure (2017) (23)
- Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose–Response Curves in Worsening Refractory Congestive Heart Failure (2015) (23)
- Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial (2017) (23)
- Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. (2020) (23)
- A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 (2020) (22)
- Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. (2016) (22)
- Redefining biomarkers in heart failure (2018) (22)
- Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients (2013) (22)
- The emerging role of multi-detector computed tomography in heart failure. (2007) (22)
- Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: Development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT (2016) (22)
- Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis (2017) (22)
- Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. (2020) (22)
- Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. (2017) (22)
- New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. (2016) (21)
- Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (21)
- Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. (2016) (21)
- Antecedents of self-care in adults with congenital heart defects. (2015) (21)
- Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.). (2014) (21)
- Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial (2017) (21)
- Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. (2019) (21)
- Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. (2019) (21)
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. (2020) (21)
- Myocardial deformation imaging of the systemic right ventricle by two-dimensional strain echocardiography in patients with d-transposition of the great arteries. (2009) (21)
- Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice (2020) (20)
- Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. (2021) (20)
- A simple score for early risk stratification in acute heart failure. (2017) (20)
- Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
- Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study (2014) (20)
- Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure) (2017) (20)
- Diastolic Dysfunction in Patients with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results from the CHART Study. (2020) (20)
- Heart Failure in Hypertension (2012) (20)
- Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study. (2015) (20)
- Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial (2021) (20)
- Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. (2022) (20)
- An economic evaluation of a self-care intervention in persons with heart failure and diabetes. (2015) (20)
- Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial (2019) (19)
- Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan (2020) (19)
- Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older AdultsClinical Perspective (2014) (19)
- Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. (2019) (19)
- Value of cardiac CT in patients with heart failure (2009) (19)
- Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart (2015) (19)
- Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial (2021) (19)
- Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). (2015) (19)
- Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle (2018) (19)
- Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. (2017) (19)
- The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF (2020) (19)
- Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure (2013) (18)
- Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). (2016) (18)
- Impact of Incident Heart Failure on Body Composition Over Time in the Health, Aging, and Body Composition Study Population (2017) (18)
- Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure (2018) (18)
- Timely Management of New-Onset Heart Failure. (2019) (18)
- Why Clinicians Should Care About the Cardiac Interstitium. (2019) (18)
- Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial (2022) (18)
- Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure (2018) (18)
- Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings (2021) (17)
- Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction (2020) (17)
- Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial (2018) (17)
- Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study (2019) (17)
- Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry (2021) (17)
- β1-Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications. (2020) (17)
- Fasting plasma glucose and incident heart failure risk: a population-based cohort study and new meta-analysis. (2014) (17)
- Mobile health applications in cardiovascular research. (2018) (17)
- Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial (2021) (17)
- Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction (2021) (17)
- Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial (2020) (17)
- Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. (2016) (17)
- An Intervention to Improve Physical Function and Caregiver Perceptions in Family Caregivers of Persons With Heart Failure (2020) (17)
- INTERMACS Profiles and Outcomes Among Non-Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction. (2018) (17)
- Redefining the role of biomarkers in heart failure trials: expert consensus document (2017) (17)
- Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF (2021) (16)
- Metformin use in patients with diabetes mellitus and heart failure: friend or foe? (2010) (16)
- Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: findings from the DIG stroke sub-study. (2010) (16)
- Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial (2016) (16)
- Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map (2021) (16)
- Systemic inflammation and functional capacity in elderly heart failure patients (2018) (16)
- Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. (2020) (16)
- Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. (2017) (16)
- Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction? (2006) (16)
- Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. (2019) (16)
- Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. (2020) (16)
- Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial (2021) (16)
- Site selection for heart failure clinical trials in the USA (2015) (16)
- Platelet-Derived Growth Factor in Heart Failure. (2016) (16)
- Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure (2021) (16)
- Salt, No Salt, or Less Salt for Patients With Heart Failure? (2020) (16)
- Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial (2017) (16)
- Optimizing Foundational Therapies in Patients With HFrEF (2022) (15)
- Exercise Capacity, Heart Failure Risk, and Mortality in Older Adults: The Health ABC Study. (2017) (15)
- Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. (2014) (15)
- Current Status of Mechanical Circulatory Support: A Systematic Review (2012) (15)
- ASC Methylation and Interleukin-1&bgr; Are Associated with Aerobic Capacity in Heart Failure (2017) (15)
- Development and Validation of Machine Learning–Based Race-Specific Models to Predict 10-Year Risk of Heart Failure (2021) (15)
- The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. (2015) (15)
- Serum resistin: physiology, pathophysiology and implications for heart failure. (2010) (15)
- Left ventricular assist device implantation via left thoracotomy: alternative to repeat sternotomy. (2002) (15)
- The 20 most-cited articles in echocardiography literature (2017) (15)
- Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. (2019) (15)
- Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study (2020) (15)
- Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. (2022) (15)
- Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination (2015) (15)
- Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. (2018) (15)
- Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure (2015) (15)
- Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2012) (15)
- Presence and extent of coronary artery disease by cardiac computed tomography and risk for acute coronary syndrome in cocaine users among patients with chest pain. (2009) (15)
- In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable (2021) (15)
- Association of electrocardiogram abnormalities and incident heart failure events. (2014) (15)
- Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists (2018) (15)
- In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. (2016) (14)
- Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia (2018) (14)
- Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia (2019) (14)
- Association of Physical Activity or Fitness With Incident Heart FailureCLINICAL PERSPECTIVE (2015) (14)
- Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. (2019) (14)
- Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). (2019) (14)
- The Vulnerable Phase of Heart Failure (2018) (14)
- Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial. (2020) (14)
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
- Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. (2018) (14)
- Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective (2020) (14)
- Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism (2021) (14)
- Moving away from symptoms‐based heart failure treatment: misperceptions and real risks for patients with heart failure (2016) (14)
- CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. (2021) (14)
- Predictors of heart failure development in type 2 diabetes: a practical approach (2019) (14)
- Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. (2016) (14)
- ‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor (2021) (14)
- The Three-Decade Long Journey in Heart Failure Drug Development. (2017) (13)
- Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. (2019) (13)
- Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations (2017) (13)
- The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications (2020) (13)
- Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (13)
- DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases (2021) (13)
- Salt, No Salt or Less Salt For Heart Failure Patients? (2019) (13)
- Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis (2020) (13)
- Advanced cancer is also a heart failure syndrome: a hypothesis (2020) (13)
- Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. (2021) (13)
- Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. (2020) (13)
- Risk Profiles in Heart Failure (2020) (13)
- Usefulness of cardiac index and peak exercise oxygen consumption for determining priority for cardiac transplantation. (2010) (13)
- Prevalence of impaired coronary flow reserve and its association with left ventricular diastolic function in asymptomatic individuals with major cardiovascular risk factors (2011) (13)
- Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial. (2022) (13)
- Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial (2022) (13)
- Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure (2020) (13)
- Assessment of the presence and extent of coronary collateralization by coronary computed tomographic angiography in patients with total occlusions (2009) (13)
- Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes (2022) (13)
- Relationship between heart failure and lipids: the paradigm continues to evolve. (2007) (12)
- Novel Trial Design: CHIEF-HF (2021) (12)
- Pathophysiology, and Clinical Implications The Sympathetic Nervous System in Heart Failure: Physiology, (2009) (12)
- Availability and Use of Shared Data From Cardiometabolic Clinical Trials (2017) (12)
- Targeting priority populations to reduce disparities in cardiovascular care: health equity for all. (2014) (12)
- Impact of Anemia and the Effect of Empagliflozin in HFrEF: findings from EMPEROR-Reduced. (2021) (12)
- Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials (2018) (12)
- Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). (2019) (12)
- Utility of positron emission tomography for drug development for heart failure. (2016) (12)
- Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT (2017) (12)
- How well do we represent ourselves: an analysis of cardiology fellowships website content. (2020) (12)
- Improving Postdischarge Outcomes in Acute Heart Failure (2018) (12)
- Race and the natural history of chronic heart failure: a propensity-matched study. (2008) (12)
- Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years (2018) (12)
- Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy (2020) (12)
- Clinical aspects of heart failure in individuals with diabetes (2019) (12)
- Noninvasive detection of coronary atherosclerotic plaque by multidetector row computed tomography (2005) (12)
- Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). (2016) (12)
- Biomarker Profile of Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction: Insights from the RELAX Trial. (2019) (11)
- Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care (2018) (11)
- Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? (2019) (11)
- Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. (2019) (11)
- Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). (2017) (11)
- Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions (2022) (11)
- Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. (2022) (11)
- Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial (2022) (11)
- Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) (2018) (11)
- Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials (2020) (11)
- Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia (2021) (11)
- Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials (2018) (11)
- Nomenclature in heart failure: a call for objective, reproducible, and biologically‐driven terminology (2018) (11)
- Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. (2021) (11)
- Treatment of Diabetes in Patients with Heart Failure (2018) (11)
- Serum chloride in heart failure: a salty prognosis (2016) (11)
- Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan (2020) (11)
- Right Ventricular Function in Adult Patients with Eisenmenger Physiology: Insights from Quantitative Echocardiography (2010) (11)
- Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial (2018) (11)
- Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial (2020) (11)
- Iron deficiency and cardiovascular disease (2022) (10)
- Prefrailty, impairment in physical function, and risk of incident heart failure among older adults (2021) (10)
- Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. (2021) (10)
- Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials (2022) (10)
- Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019. (2022) (10)
- Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? (2017) (10)
- Prediction of worsening heart failure events and all‐cause mortality using an individualized risk stratification strategy (2020) (10)
- Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. (2021) (10)
- Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure: The PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) Pilot Study. (2020) (10)
- Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design (2017) (10)
- Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. (2016) (10)
- Scope of heart failure hospitalization. (2012) (10)
- Incident coronary revascularization and subsequent mortality in chronic heart failure: a propensity-matched study. (2010) (10)
- Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). (2021) (10)
- Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. (2021) (10)
- Incentivizing recruitment and retention to address enrollment challenges in clinical research. (2013) (10)
- The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure? (2017) (10)
- Acute Dyspnea and Decompensated Heart Failure. (2018) (10)
- Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency (2021) (10)
- Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists (2015) (10)
- Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? (2017) (10)
- Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure (2020) (9)
- Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction (2021) (9)
- Acutely decompensated versus acute heart failure: two different entities (2019) (9)
- Therapeutic Advances in the Management of Cardiogenic Shock (2019) (9)
- Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress - not Problem. (2021) (9)
- Critical reappraisal of pulmonary artery catheterization and invasive hemodynamic assessment in acute heart failure (2013) (9)
- Novel Endpoints for Heart Failure Clinical Trials (2017) (9)
- Effect of Obesity on Response to Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction. (2021) (9)
- Iron de fi ciency and cardiovascular disease (2022) (9)
- Heart failure guidelines: What's new? (2017) (9)
- Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study (2021) (9)
- Dilemmas of Blood Pressure Management for Heart Failure Prevention (2011) (9)
- History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. (2019) (9)
- Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? (2016) (9)
- Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). (2013) (9)
- Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency (2020) (9)
- Heart Failure: A Global Pandemic and Not Just a Disease of the West. (2015) (9)
- Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. (2019) (9)
- Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial (2019) (9)
- Heart Failure Guidelines on Pharmacotherapy. (2017) (8)
- Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. (2021) (8)
- Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response (2015) (8)
- Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event (2021) (8)
- Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study (2009) (8)
- Integrating electronic health records into the study of heart failure: promises and pitfalls (2017) (8)
- Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. (2021) (8)
- The need for increased pragmatism in cardiovascular clinical trials (2022) (8)
- AHA Policy Statement Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association (2011) (8)
- Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy (2017) (8)
- Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. (2021) (8)
- Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. (2022) (8)
- Pulmonary Function Testing and Outcomes in Subjects With Heart Failure Listed for Heart Transplantation (2015) (8)
- Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. (2018) (8)
- Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure (2022) (8)
- Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study (2020) (8)
- Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. (2022) (8)
- Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial (2022) (8)
- Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads (2016) (8)
- Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. (2020) (8)
- Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach. (2008) (8)
- Task Force on Practice Guidelines Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A (2013) (8)
- Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. (2017) (8)
- Victims of Success in Failure. (2020) (8)
- Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. (2016) (8)
- Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
- Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction (2022) (8)
- Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). (2014) (8)
- Trends in Consent for Clinical Trials in Cardiovascular Disease (2016) (8)
- Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency (2022) (8)
- Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events (2016) (8)
- N8‐Acetylspermidine: A Polyamine Biomarker in Ischemic Cardiomyopathy With Reduced Ejection Fraction (2020) (7)
- Transmethylamine‐N‐Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV (2021) (7)
- Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction (2020) (7)
- Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. (2022) (7)
- Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. (2020) (7)
- A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. (2018) (7)
- Registries and health care quality improvement. (2009) (7)
- Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone (2021) (7)
- Therapeutic Advances in the Management of Acute Decompensated Heart Failure (2019) (7)
- Combined aquaretic and diuretic therapy in acute heart failure (2017) (7)
- Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Sub-Study. (2021) (7)
- Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. (2019) (7)
- Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. (2017) (7)
- What's Next for Acute Heart Failure Research? (2018) (7)
- Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials (2020) (7)
- SGLT-2 inhibitors in heart failure: a new therapeutic avenue (2019) (7)
- Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? (2021) (7)
- Expanded algorithm for managing patients with acute decompensated heart failure (2018) (7)
- Advanced cancer is also a heart failure syndrome: a hypothesis (2021) (7)
- 842-5 Anemia is common in patients with heart failure seen in specialty and community cardiology clinics: Results from the STAMINA: HFP registry (study of anemia in a heart failure population) (2004) (7)
- Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial (2021) (7)
- Clinical Scores and Echocardiography for Right Ventricular Failure Risk Prediction after Implantation of Continuous-Flow Left Ventricular Assist Devices (2013) (7)
- Frailty, Guideline-Directed Medical Therapy, and Outcomes in Heart Failure With Reduced Ejection Fraction (2022) (7)
- Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. (2020) (7)
- Novel potassium binders as enabling therapy in heart failure (2019) (7)
- The Limitations of Symptom-based Heart Failure Management (2019) (7)
- Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure (2018) (7)
- Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. (2018) (7)
- Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment (2018) (7)
- Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial (2022) (7)
- Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. (2021) (7)
- Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced (2022) (7)
- Contextualizing Risk Among Patients With Heart Failure. (2021) (7)
- Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation (2022) (7)
- Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST‐AHF trial (2018) (6)
- Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function (2020) (6)
- Abstract 2204: Coronary Multidetector Computed Tomography in the Assessment of Patients with Acute Chest Pain (2006) (6)
- Clinical trials in acute heart failure: beginning of the end or end of the beginning? (2017) (6)
- Challenges and the innovations in the care of advanced heart failure patients during COVID-19 (2021) (6)
- Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction (2020) (6)
- Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. (2021) (6)
- Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF (2020) (6)
- Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes (2021) (6)
- Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. (2017) (6)
- Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial (2022) (6)
- A new educational program in heart failure drug development: the Brescia international master program (2018) (6)
- Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME (2021) (6)
- Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure (2022) (6)
- Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. (2021) (6)
- Medicaid Expansion and Utilization of Antihyperglycemic Therapies (2020) (6)
- Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
- Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. (2020) (6)
- Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End PointsCLINICAL PERSPECTIVE (2016) (6)
- EXTRACELLULAR MATRIX EXPANSION IN NON-INFARCTED MYOCARDIUM IS ASSOCIATED WITH SUBSEQUENT DEATH, HOSPITALIZATION FOR HEART FAILURE, OR BOTH ACROSS THE EJECTION FRACTION SPECTRUM (2014) (6)
- Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced (2022) (6)
- CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure (2015) (6)
- Rapid onset and resolution of cardiogenic shock in a patient with pheochromocytoma. (2009) (6)
- Diagnosis and Prevention of Hypertensive Heart Failure. (2019) (6)
- Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). (2019) (6)
- Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. (2020) (6)
- New treatments for hyperkalaemia: clinical use in cardiology (2019) (6)
- Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. (2021) (6)
- Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. (2022) (6)
- Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials (2021) (6)
- Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’ (2021) (6)
- EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL (2019) (6)
- Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction. (2021) (6)
- The real world of de novo heart failure: the next frontier for heart failure clinical trials? (2020) (6)
- Updates on Device-Based Therapies for Patients with Heart Failure (2018) (6)
- Heart failure/transplant: abstractIncidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure (2004) (5)
- The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. (2017) (5)
- Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials (2020) (5)
- Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial (2021) (5)
- Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. (2022) (5)
- Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure. (2020) (5)
- Impact of chronic kidney disease in patients undergoing percutaneous or surgical carotid artery revascularization: Insights of the healthcare cost and utilization Project's National Inpatient Sample. (2016) (5)
- Validity of Coronary Artery Disease Consortium Models for Predicting Obstructive Coronary Artery Disease & Cardiovascular Events in Patients with Acute Chest Pain Considered for Coronary Computed Tomographic Angiography. (2018) (5)
- Design of a "Lean" Case Report Form for Heart Failure Device Development. (2019) (5)
- Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced (2022) (5)
- Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. (2011) (5)
- Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults (2019) (5)
- Medical Therapy for Acute Decompensated Heart Failure: What Recent Clinical Trials Have Taught Us About Diuretics and Vasodilators (2012) (5)
- Cardiovascular Risk Factors and Complications in Patients Infected with COVID-19: A Systematic Review (2020) (5)
- Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial (2022) (5)
- Expanding the scope of the "polypill" to heart failure. (2013) (5)
- The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP‐HF (2022) (5)
- MDCT-based coronary angiography: a Rosetta stone for understanding coronary disease? (2006) (5)
- Epirubicin and long‐term heart failure risk in breast cancer survivors (2018) (5)
- Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. (2021) (5)
- Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. (2021) (5)
- Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. (2020) (5)
- Rationale and Design of the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy in Heart Failure (ATHENA-HF) Trial (2016) (5)
- What can heart failure trialists learn from oncology trialists? (2021) (5)
- Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. (2022) (5)
- Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. (2022) (5)
- Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. (2022) (5)
- Aspirin use is associated with increased risk for incident heart failure: a patient‐level pooled analysis (2021) (5)
- Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense? (2014) (5)
- Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies). (2022) (5)
- Clinical research in Africa And Middle East: Roadmap for reform and harmonisation of the regulatory framework and sustainable capacity development (2019) (5)
- Myocardial fibrosis is associated with subsequent death and hospitalization for heart failure in obese adults (2015) (5)
- Current perspectives on hydralazine and nitrate therapies in heart failure. (2014) (5)
- Chronic stable angina: pathophysiology and innovations in treatment. (2011) (5)
- Heart Failure (2022) (5)
- Recognizing the Significance of Outpatient Worsening Heart Failure (2020) (5)
- Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis (2022) (5)
- Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial (2021) (4)
- Iron Deficiency in CKD Without Concomitant Anemia (2021) (4)
- Comorbid conditions in heart failure: an unhappy marriage. (2014) (4)
- Heart rate in heart failure with preserved ejection fraction: target or marker? (2017) (4)
- Istaroxime in acute heart failure: the holy grail is at HORIZON? (2020) (4)
- Reassessing the use of vasodilators in heart failure (2012) (4)
- Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure: Finding the "Sweet Spot". (2018) (4)
- Natriuretic peptide-guided management in heart failure. (2015) (4)
- Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors over Time in Heart Failure with Reduced Ejection Fraction. (2021) (4)
- The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure (2020) (4)
- Impact of atrial fibrillation in patients with chronic kidney disease undergoing transcatheter aortic valve replacement: Insights of the Healthcare Cost and Utilization Project's National Inpatient Sample. (2017) (4)
- Past, present, and future of acute heart failure clinical trials—a high‐risk population in search of a strategy (2018) (4)
- Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event (2021) (4)
- Roxadustat for Anemia in Patients with Chronic Kidney Disease. (2020) (4)
- Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. (2021) (4)
- Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study (2020) (4)
- Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. (2016) (4)
- Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. (2021) (4)
- Systolic Blood Pressure and Incident Heart Failure in the Elderly (2013) (4)
- Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. (2021) (4)
- Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum (2022) (4)
- TEMPORAL TRENDS IN CARDIAC REHABILITATION REFERRAL AMONG PATIENTS HOSPITALIZED WITH HEART FAILURE: ANALYSIS FROM AMERICAN HEART ASSOCIATION GET WITH THE GUIDELINES-HEART FAILURE REGISTRY (2015) (4)
- Machine Learning to Define Phenotypes and Outcomes of Patients Hospitalized for Heart Failure with Preserved Ejection Fraction: Findings from ASCEND-HF. (2022) (4)
- Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events. (2004) (4)
- Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. (2015) (4)
- CORONARY MICROVASCULAR DYSFUNCTION AND CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (2019) (4)
- The elusive scourge of sudden cardiac death: is rational decision making possible? Should there be standards of risks and predictions in medicine? (2007) (4)
- The importance of managing diabetes correctly to prevent heart failure (2011) (4)
- Blunted hemodynamic response and reduced oxygen delivery with exercise in anemic heart failure patients with systolic dysfunction. (2007) (4)
- Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study. (2021) (4)
- ACCF/AHA Practice Guideline (2013) (4)
- Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. (2020) (4)
- DISCHARGE INITIATION OF ACE INHIBITORS OR ARBS IS ASSOCIATED WITH SIGNIFICANTLY LOWER 30-DAY ALL-CAUSE READMISSION IN HOSPITALIZED OLDER PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION (2014) (4)
- From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum (2020) (4)
- Ten lessons from the EMPEROR‐Reduced trial (2020) (4)
- FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY (2018) (3)
- Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. (2020) (3)
- Patient‐reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life (2020) (3)
- Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model (2021) (3)
- Stability of Changes in Health Status: Next Step in Comprehensively Assessing Patient-Reported Outcomes. (2022) (3)
- Heart Failure in Pregnancy: A Problem Hiding in Plain Sight (2019) (3)
- Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy? (2015) (3)
- Can we trust a smartwatch ECG? Potential and limitations (2021) (3)
- Assessment of Heterogeneity in Heart Failure–Related Meta-Analyses (2020) (3)
- Impact of optimal heart failure medical therapy on heart transplant listing. (2006) (3)
- Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. (2018) (3)
- Optimal Endpoints of Acute Heart Failure Therapy (2018) (3)
- Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled. (2022) (3)
- Abstract 16610: Efficacy and Safety of Sodium Zirconium Cyclosilicate to Treat Hyperkalemia Among Patients Taking Renin-Angiotensin-Aldosterone System Inhibitors in a 12-Month, Open-Label, Phase 3 Study: A Post Hoc Subgroup Analysis (2017) (3)
- Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial (2022) (3)
- Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis (2020) (3)
- Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations (2015) (3)
- A Struggle to SURVIVE: To Abandon or not to Abandon Levosimendan? (2007) (3)
- Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results (2020) (3)
- Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency (2022) (3)
- Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial (2022) (3)
- Cardiac Imaging in Dialysis Patients (2020) (3)
- Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF (2022) (3)
- Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials. (2021) (3)
- Post‐discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial (2019) (3)
- Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation? (2015) (3)
- Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other (2021) (3)
- Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. (2020) (3)
- Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced (2022) (3)
- Sex-Related Differences in Early- and Long-Term Mortality After Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis. (2020) (3)
- SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY (2018) (3)
- Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry (2020) (3)
- Health care quality improvement: the devil really is in details. (2008) (3)
- Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. (2022) (3)
- Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications (2020) (3)
- Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. (2019) (3)
- Revisiting cardiac injury during acute heart failure: further characterization and a possible target for therapy. (2015) (3)
- Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. (2017) (3)
- Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? (2014) (3)
- Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials. (2020) (3)
- Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials (2017) (3)
- Risk Factors for Development of Heart Failure (2007) (3)
- Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry (2021) (3)
- Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey. (2022) (3)
- Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). (2015) (3)
- Heart Failure (2011) (3)
- Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate? (2019) (3)
- Contemporary outcomes of optimally treated heart failure patients with sleep apnea. Case for urgency in evaluation of newer interventions? From the Atlanta Cardiomyopathy Consortium. (2013) (3)
- Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction (2022) (3)
- Mineralocorticoid Receptor Antagonism in Acute Heart Failure (2015) (3)
- Palliative Care and Cardiovascular Disease and Stroke (2016) (3)
- Progress or lack of progress in hospitalized heart failure (2013) (3)
- Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure (2022) (3)
- Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia (2019) (3)
- Regional variation in heart failure hospitalizations: biology, barrier, or bias? (2008) (2)
- Improving Post-Discharge Outcomes in Acute Heart Failure (2018) (2)
- Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. (2018) (2)
- Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. (2021) (2)
- Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology (2022) (2)
- Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). (2019) (2)
- LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY (2019) (2)
- Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure: The Health ABC Study. (2022) (2)
- Differences Among Hospitals in Delivery of Care for Heart Failure (2003) (2)
- REPORT‐HF: the unique blend of global heart failure registry and longitudinal cohort study (2015) (2)
- Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. (2020) (2)
- Long-term response of the left ventricle to cardiac resynchronization therapy: insights from standard and strain echocardiography. (2011) (2)
- Heart Failure Prevention for All: Treatment Is Good, Prevention Is Better. (2020) (2)
- Vagus Nerve Stimulation for Chronic Heart Failure: Differences in Therapy Delivery and Clinical Efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (2)
- Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. (2022) (2)
- Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. (2018) (2)
- Novel Biomarkers of Oxidative Stress are Associated with Risk of Death and Hospitalization in Patients with Heart Failure (2018) (2)
- Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. (2022) (2)
- Arterial Stiffness and Risk of Overall Heart Failure , Heart Failure With Preserved Ejection Fraction , and Heart Failure With Reduced Ejection Fraction (2017) (2)
- The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial (2019) (2)
- Targeting Mitochondrial Function in Heart Failure (2019) (2)
- Multi-Harmonic Phase Analysis of Gated Spect Myocardial Perfusion Imaging Compared With Nt-Pro-Bnp and Echocardiography for the Assessment of Left Ventricular Diastolic Function (2011) (2)
- SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy. (2022) (2)
- Revisiting hyperkalaemia guidelines: rebuttal (2018) (2)
- Abstract 196: Development and Validation of Machine Learning-based Race-specific Models to Predict 10-year Risk of Heart Failure: A Multi-cohort Analysis (2020) (2)
- Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States. (2023) (2)
- Minimal Clinically Important Difference for Six-minute Walk Test in Patients with HFrEF and Iron Deficiency. (2022) (2)
- Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department (2021) (2)
- Growing Heart Failure Burden of Hypertensive Heart Disease: A Call to Action. (2022) (2)
- De novo heart failure: where the journey begins (2019) (2)
- Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes (2019) (2)
- Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial (2022) (2)
- Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. (2022) (2)
- Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. (2021) (2)
- Abstract 203: Health Status Variations Across Practices in Outpatients With Heart Failure: Health Status Variations Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF Registry (2018) (2)
- Impact of chronic kidney disease on mortality in adults undergoing balloon aortic valvuloplasty. (2017) (2)
- Apolipoprotein A-1 Levels and Heart Failure Outcomes (2012) (2)
- Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. (2022) (2)
- Endpoints for diuresis: are we there yet? (2014) (2)
- Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. (2016) (2)
- Maternal Heart Failure (2021) (2)
- Heart failure prevention with sodium‐glucose cotransporter 2 inhibitors (2019) (2)
- Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure (2022) (2)
- Oral Sodium and Potassium Binders in Heart Failure (2015) (2)
- Effects of Angiotensin Receptor/Neprilysin Inhibitor Therapy on Amino-terminal Pro-B-Type Natriuretic Peptide and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: The PROVE-HF Study (2019) (2)
- Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. (2019) (2)
- “Fast Track” Development and Approval Process for Heart Failure Therapeutics (2017) (2)
- Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis (2021) (2)
- Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. (2022) (2)
- Angiotensin–neprilysin inhibition in de novo heart failure – starting off strong (2019) (2)
- Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial (2018) (2)
- Prescription drug spending and hospital use among Medicare beneficiaries with heart failure. (2019) (2)
- Differences in Myocardial Sympathetic Innervation and Perfusion in Patients with Ischemic Versus Non-ischemic Heart Failure (2014) (2)
- Ejection fraction in heart failure: just become Emperor's new clothes? (2021) (2)
- Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. (2021) (2)
- Treatment of heart failure with sodium glucose co‐transporter‐2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions (2019) (2)
- A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC. (2022) (2)
- An Integrated Self Care Education and Counseling Intervention for Persons with Heart Failure and Diabetes Improves Quality of Life and Physical Functioning (2014) (2)
- Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. (2022) (2)
- Classification of patients hospitalized for heart failure. (2013) (2)
- PREDICTORS OF IN-HOSPITAL MORTALITY IN PATIENTS WITH TAKOTSUBO CARDIOMYOPATHY: INSIGHTS OF THE HEALTHCARE COST AND UTILIZATION PROJECT'S NATIONAL INPATIENT SAMPLE (2016) (2)
- RELIABLE EVALUATION OF DYSPNEA (RED-ROSE): A PROSPECTIVE ANCILLARY STUDY FROM THE RENAL OPTIMIZATION STRATEGIES EVALUATION IN ACUTE HEART FAILURE (ROSE-AHF) TRIAL (2014) (2)
- From the American Heart Association Forecasting the Future of Cardiovascular Disease in the United States : A Policy Statement (2012) (2)
- Focus on Hyperkalemia Management: Expert Consensus and Economic Impacts (2017) (2)
- Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. (2022) (2)
- 842-6 Anemia is associated with reduced health status measures in patients with heart failure: Results from the STAMINA: HFP (study of anemia in a heart failure population) registry (2004) (2)
- Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure (2019) (2)
- Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. (2014) (2)
- Accelerating therapeutic discoveries for heart failure: a new public–private partnership (2022) (1)
- Serelaxin for the treatment of heart failure (2016) (1)
- Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure. (2022) (1)
- Strategies to reduce heart failure readmissions--reply. (2014) (1)
- Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
- Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. (2022) (1)
- Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration. (2023) (1)
- Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study. (2022) (1)
- Cystatin C as a Biomarker of Worsening Renal Function in Acute Heart Failure: Insights from the DOSE Study (2011) (1)
- Increased Cardiothoracic Ratio and Adverse Outcomes in Chronic Heart Failure: A Propensity-Matched Study (2007) (1)
- CRT-700.11 Impact of Female Gender on 30-Day Outcomes Following Transcatheter Aortic Valve Replacement with Contemporary Valves (2018) (1)
- Failure predicting failure: The right ventricle after left ventricular assist device implantation. (2019) (1)
- Beta-Blocker Pretreatment Does Not Affect the Renoprotective Effects of Low-Dose Dopamine in Patients with Acute Decompensated Heart Failure (2010) (1)
- Improvement in renal function after left ventricular assist device placement (2004) (1)
- Vascular Biology and Microcirculation Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction (2018) (1)
- Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter? (2019) (1)
- Cardiac 64-Slice Multi-Detector Computed Tomography Detection of Infarct Size in Patients with Post-Infarct Left Ventricular Dysfunction: A Comparative Study with SPECT Imaging and Cardiac Biomarkers (2006) (1)
- Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer. (2023) (1)
- Response to Letter Regarding Article, “Effect of Short Call Admissions on Length of Stay and Quality of Care for Acute Decompensated Heart Failure” (2009) (1)
- Major Depression and Anxiety Among Patients Hospitalized with Heart Failure. (2020) (1)
- Abstract 19403: Gender and Socioeconomic Disparities With Health Status in Outpatients With Heart Failure: Insights From the CHAMP-HF Registry (2017) (1)
- 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME (2020) (1)
- Anemia in heart failure may warrant more aggressive listing for cardiac transplantation. (2006) (1)
- Heart failure: do we deliver quality care? (2003) (1)
- Reply (2013) (1)
- Sudden Death Following Hospitalization for Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial) (2018) (1)
- BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL (2021) (1)
- FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL (2021) (1)
- Low- versus Moderate-Sodium Diet in Patients with Recent Hospitalization for Heart Failure: The PROHIBIT Sodium Pilot Study (2019) (1)
- Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth? (2021) (1)
- Diabetes Mellitus in Patients With Heart Failure: Bad for All, Worse for Some. (2017) (1)
- Heart failure with preserved ejection fraction: a bouillabaisse. (2014) (1)
- Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy (2020) (1)
- INTERVENE‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction (2021) (1)
- Abstract 052: Hypertensive Diseases In Pregnancy And Hemodynamic Stress Later In Life (2021) (1)
- Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction. (2022) (1)
- Reactive Hyperemia is Decreased in Black Subjects with Heart Failure Despite Equal Prescription of Guideline-Directed Medical Therapy (2018) (1)
- Little at a time: trying to understand the battery of benefits of sodium–glucose contransporter 2 inhibitors in heart failure (2023) (1)
- Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS‐HF trial (2019) (1)
- Liraglutide for Adolescents with Obesity. (2020) (1)
- Statement From the American Heart Association Forecasting the Future of Cardiovascular Disease in the United States: A Policy (2011) (1)
- Mechanisms, and Future Directions Hydralazine and Isosorbide Dinitrate in Heart Failure : Historical Perspective, (2012) (1)
- Baseline Hypokalemia and Long-Term Outcomes in Ambulatory Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and New York Heart Association Class III-IV: A Propensity-Matched Study of Beta-Blocker Evaluation of Survival Trial (BEST) (2016) (1)
- ADHERENCE, PREDICTORS OF ADHERENCE AND OUTCOMES ASSOCIATED WITH SELF-CARE RECOMMENDATIONS AMONG HEART FAILURE PATIENTS (2011) (1)
- Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. (2021) (1)
- Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure? (2023) (1)
- Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy (2022) (1)
- LIVING IN A FOOD DESERT IS ASSOCIATED WITH AN EARLY HAZARD OF DEATH AND HOSPITALIZATION IN HEART FAILURE PATIENTS (2017) (1)
- Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure (1)
- Corrigendum to ‘Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart’ [Eur J Heart Fail] 2015 August;17(8): 760–763. doi:10.1002/ejhf.315 (2015) (1)
- Neighborhood Household Income and Trends in 30-Day Readmission for Patients With Heart Failure. (2022) (1)
- Chronic Kidney Disease and Higher Risk of 30-Day All-Cause Readmissions in Heart Failure: Findings from a Propensity-Matched Study (2014) (1)
- Evaluating High-Risk, Vulnerable Plaques with Integrated PET/CT (2007) (1)
- Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank (2022) (1)
- 1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) (2020) (1)
- Renoprotective and Potassium Sparing Effects of Low Dose Dopamine in Acute Decompensated Heart Failure: Preliminary Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial (2009) (1)
- Orphan Drug Development in Cardiovascular Medicine (2020) (1)
- Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart (2021) (1)
- CLINICAL PROFILES, MEDICAL THERAPIES, AND OUTCOMES AMONG PATIENTS HOSPITALIZED FOR HF ACROSS THE SPECTRUM OF KIDNEY FUNCTION: THE GWTG-HF REGISTRY (2021) (1)
- The role of sodium glucose co-transporter inhibitors in heart failure prevention. (2020) (1)
- New heart failure diagnostic and prognostic biomarkers discovered using capillary electrophoresis coupled to mass spectroscopy (2013) (1)
- Putting the Puzzle Together: SGLT2 Inhibitors from Prevention to Treatment of Heart Failure. (2022) (1)
- Abstract 11307: Interleukin-1β and Methylation of Apoptosis Associated Speck-Like Protein Containing a Caspase Recruitment Domain Are Associated With Aerobic Capacity in Heart Failure (2016) (1)
- RATIONALE AND METHODS OF THE PROSPECTIVE STUDY OF BIOMARKERS, SYMPTOM IMPROVEMENT AND VENTRICULAR REMODELING DURING ENTRESTO THERAPY FOR HEART FAILURE (PROVE-HF) STUDY (2017) (1)
- ELDERLY PATIENTS ARE LESS LIKELY TO RECEIVE EVIDENCE-BASED MEDICATIONS INDICATED FOR SYSTOLIC HEART FAILURE: RESULTS FROM THE STUDY OF ANEMIA IN A HEART FAILURE POPULATION (STAMINA-HFP) REGISTRY (2010) (1)
- Disparities in discharge disposition after hospitalizations for decompensated heart failure. (2020) (1)
- Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019. (2022) (1)
- Effects of Canagli fl ozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes (2017) (1)
- Adults with congenital heart disease: growing pains. (2014) (1)
- The prognostic importance of cardiac output response to exercise in the beta-blocker era of heart failure therapy (2004) (1)
- Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF. (2023) (1)
- Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure (2021) (1)
- A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF (2014) (1)
- Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. (2022) (1)
- Medication-Attributable Adverse Events in Heart Failure Trials. (2023) (1)
- NT-PROBNP IN ACUTE DECOMPENSATED HEART FAILURE: FINDINGS FROM THE ASCEND-HF STUDY (2013) (1)
- DIURETIC DOSE AND OUTCOMES AMONG HOSPITALIZED HEART FAILURE PATIENTS: INSIGHTS FROM THE EVEREST TRIAL (2013) (1)
- Congestive Heart Failure special issue on advanced heart failure. (2011) (1)
- Hostile Work Environment: A Case of the Emperor's New Clothes. (2021) (1)
- Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. (2023) (1)
- Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO) (2018) (1)
- Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool? (2017) (1)
- The worst symptom visual analogue scale: a prospective ancillary study from the renal optimization strategies evaluation in acute heart failure (rose-AHF) trial (2014) (1)
- Sodium–glucose co‐transporter 2 inhibitors: ‘a tale of two sisters’, diabetes and heart failure (2020) (1)
- Quest for Pathophysiological Understanding of Heart Failure With Preserved Ejection Fraction: Stiffened Resolve, Compliant Approach. (2017) (1)
- Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). (2021) (1)
- REAL WORLD STUDY OF CHARACTERISTICS AND OUTCOMES OF COMMERCIALLY INSURED PATIENTS WITH STABLE VERSUS WORSENING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION (2020) (1)
- Arterial Stiffness and risk of Overall Heart Failure, Heart Failure with Preserved Ejection Fraction, and Heart Failure with Reduced Ejection Fraction: The Health ABC Study (2017) (1)
- Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy. (2022) (1)
- Target trial emulations: bridging the gap between clinical trial and real‐world data (2021) (1)
- Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) (2021) (1)
- Abstract 2004: Usefulness of Coronary CT Angiography in the Early Triage of Patients with Acute Chest Pain (2008) (1)
- Reply: Are Changes in Serum Potassium Levels During Admissions for Acute Decompensated Heart Failure Irrelevant for Prognosis: The End of the Story? (2015) (1)
- Role of Cardiac Contractility Modulation in Heart Failure with a Higher Ejection Fraction. (2022) (1)
- Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study (2022) (1)
- The Association of Digital Health Application Use with Heart Failure Care and Outcomes: Insights from CONNECT-HF. (2022) (1)
- Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. (2018) (1)
- Causal Analysis of the TOPCAT Trial: Spironolactone for Preserved Cardiac Function Heart Failure (2022) (1)
- Abstract 15468: Healthcare Resource Utilization and Costs Among US Patients With Worsening Chronic Heart Failure: Analysis of PINNACLE Registry Linked With Claims Data (2017) (1)
- Sex-based Differences in Biomarkers, Quality of Life, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan (2020) (1)
- Association of Major and Minor ECG AbnormalitiesWithCoronaryHeartDiseaseEvents (2012) (1)
- PLASMA ENDOTHELIN-1 INDEPENDENTLY PREDICTS 180-DAY MORTALITY IN ACUTE HEART FAILURE: AN ASCEND-HF SUB-STUDY (2015) (1)
- Abstract 12886: In-hospital and Early Post-discharge Troponin Elevations Among Patients Hospitalized for Heart Failure: Insights From the ASTRONAUT Trial (2016) (1)
- Risk Prediction of Incident Heart Failure in a Preventive Cardiology Clinic: Validation of the Health ABC Heart Failure Risk Score With Natriuretic Peptide Testing (2010) (1)
- Abstract 12794: Hospital Length of Stay and Readmissions Post Heart Failure Hospitalization in the EVEREST Trial (2014) (1)
- Troponin is unrelated to outcomes in heart failure patients discharged from the emergency department (2022) (1)
- Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Beneficiaries With Systolic Heart Failure Eligible for Spironolactone Therapy (2014) (1)
- The science of quality-of-life-directed care! (2011) (1)
- Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved (2022) (1)
- MRI feature tracking strain profiles distinguish patients with left ventricular systolic and diastolic dysfunction with and without clinical heart failure (2016) (1)
- Albuminuria and Heart Failure: JACC State-of-the-Art Review. (2023) (1)
- Biomarkers in acute heart failure: from risk markers to therapeutic targets. (2013) (1)
- N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes (1)
- Mechanisms of current therapeutic strategies for heart failure: more questions than answers? (2022) (1)
- Effects of Canagli fl ozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes (2017) (1)
- Patient‐reported outcome measures and patient engagement in heart failure clinical trials: multi‐stakeholder perspectives (2023) (1)
- Kidney function assessment and endpoint ascertainment in clinical trials. (2021) (1)
- SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives (2021) (1)
- Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. (2021) (1)
- Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease (2022) (1)
- Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum. (2023) (1)
- 'Normal Weight' Is Really Not Normal in Chronic Disease. (2022) (1)
- Current Emergency Department Disposition of Patients with Acute Heart Failure: An Opportunity for Improvement. (2022) (1)
- More risk factors affecting heart failure outcomes! Time for hope or despair? (2005) (1)
- In reply: Cardiorenal syndrome (2006) (1)
- Abstract 224: Characterizing Quality of Life Responses and Physical Functioning Improvements to an Integrated Self-care Intervention for Persons With Co-morbid Heart Failure and Diabetes (2017) (1)
- APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION (2020) (1)
- The Importance of Worsening Heart Failure: Hiding in Plain Sight. (2022) (1)
- Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry (2021) (1)
- How to Best Identify Elderly Individuals Who May Develop Heart Failure (2016) (0)
- Atherosclerotic Plaque Detection by Multi-detector Computed Tomography (2006) (0)
- Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study. (2023) (0)
- Race/Ethnic Differences in the Epidemiology of Graft Failure in a Contemporary Cohort (2014) (0)
- Abstract 12706: Novel Correlates of Depressive Symptoms in Family Caregivers of Heart Failure Patients (2016) (0)
- The Reply. (2021) (0)
- HEART FAILURE WITH REDUCED EJECTION FRACTION CARE PATTERNS IN THE OUTPATIENT PRACTICE SETTING: INITIAL FINDINGS FROM CHAMP-HF (2017) (0)
- In-Hospital Inotropes and Outcomes in Ischemic vs. Nonischemic Cardiomyopathy: Insights from the ESCAPE Trial (2012) (0)
- Atrial fibrillation and heart failure: it takes two to tango. Foreword. (2013) (0)
- Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure (2008) (0)
- CRT-100.03 Cardiogenic Shock and ST-elevation Myocardial Infarction: Do Patients With Prior CABG Or Prior PCI Do Better? (2018) (0)
- Abstract P169: Incidence and Predictors of Outpatient Heart Failure in a Large Insured Population (2011) (0)
- Abstract 138: Impact of Depressive Disorder on Access to Care and Quality of Care in Veterans With Cardiovascular Disease (2017) (0)
- Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories – findings from the EMPEROR-Pooled (2022) (0)
- Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox? (2021) (0)
- Abstract 242: Influenza Seasonal Peak in Critical Congestive Heart Failure Hospitalizations (2017) (0)
- Anxiety Symptoms, Major Clinical Events, and Healthcare Resource Utilization in Outpatients with Heart Failure in the Atlanta Cardiomyopathy Consortium (TACC) Study (2013) (0)
- Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF (2015) (0)
- INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL (2022) (0)
- Dilemmas With Race and Heart Failure Treatment. (2016) (0)
- Abstract 20566: Lower Discharge Systolic Blood Pressure (SBP) and Poor Outcomes among Hospitalized Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) and Stable Admission-to-Discharge SBP (2016) (0)
- Abstract 19401: Increased Levels of Tissue Inhibitor of Metalloproteinase 1 Are Independently Associated with Adverse Outcomes in Outpatients with Heart Failure (2010) (0)
- Hemodynamic Parameters and Renal Function in Patients Hospitalized for Heart Failure (2009) (0)
- With great power comes great… reliability (2020) (0)
- Trajectory of high sensitivity c-reactive protein and incident heart failure in black adults: the jackson heart study (2023) (0)
- EJECTION FRACTION, BIOMARKERS, AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION AND THE IMPACT OF VERICIGUAT ON OUTCOMES IN THE VICTORIA TRIAL (2022) (0)
- SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence (2023) (0)
- Response from Neurolink (2002) (0)
- PULMONARY DIASTOLIC DECAY TIME IS A NOVEL INDEX ASSOCIATED WITH SEVERE HEMODYNAMIC IMPAIRMENTS IN PATIENTS WITH PULMONARY HYPERTENSION (2019) (0)
- EFFECT OF VIRTUAL PATIENT SIMULATION AT IMPROVING MANAGEMENT OF CHRONIC HYPERKALEMIA (2020) (0)
- EARLY (1-10 DAYS) READMISSION IS ASSOCIATED WITH A SIGNIFICANTLY LOWER 2-12 MONTHS POST-DISCHARGE ALL-CAUSE MORTALITY AMONG OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE WITH 30-DAY ALL-CAUSE READMISSIONS (2016) (0)
- SYSTEMIC RIGHT VENTRICULAR FUNCTION AND OUTCOMES IN ADULTS WITH D-TRANSPOSITION OF THE GREAT ARTERIES WITH ATRIAL SWITCH: THE VALUE OF ECHOCARDIOGRAPHIC QUANTIFICATION (2011) (0)
- CHARACTERIZING THE DIGITAL DIVIDE & ACCESS TO MOBILE HEALTH INTERVENTIONS IN HEART FAILURE: INSIGHTS FROM THE CONNECT-HF MHEALTH SUBSTUDY (2023) (0)
- Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game (2022) (0)
- WHY MEASURE NT-PROBNP SERIALLY IN CHRONIC HEART FAILURE? MECHANISTIC ASSOCIATIONS OF NATRIURETIC PEPTIDE SLOPE FOLLOWING INITIATION OF SACUBITRIL/VALSARTAN (2023) (0)
- 53: How Often Do Emergency Department Patients with Chest Pain Meet Eligibility Criteria for Multi-Detector Computerized Tomography of the Coronary Arteries? (2006) (0)
- Unsupervised Machine Learning To Define Acute Hfpef Phenotypes: Findings From Ascend-hf (2022) (0)
- Distribution, Treatment, and Health Record Documentation of Depression Symptoms in Heart Failure Outpatients (2010) (0)
- INITIATION OF LOOP DIURETICS HAS NO ASSOCIATION WITH 30-DAY ALL-CAUSE OR HEART FAILURE READMISSIONS OR ALL-CAUSE MORTALITY IN OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2016) (0)
- ELECTROCARDIOGRAPHIC T WAVE INVERSION IS ASSOCIATED WITH INCIDENT HEART FAILURE IN BLACK AMERICANS: THE JACKSON HEART STUDY (2023) (0)
- Heart Association Forecasting the Impact of Heart Failure in the United States : A Policy Statement From the Print (2018) (0)
- Increased Levels of Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Are Independently Associated with Adverse Outcomes in Outpatients with Heart Failure (2010) (0)
- Performance On Guideline Directed Medical Therapy Remains Low In A Cluster-randomized Trial: Results From CONNECT-HF (2022) (0)
- Detectable Cardiac Troponin I Predicts Adverse Cardiac Events and Heart Failure Hospitalizations in Stable Heart Failure Outpatients (2015) (0)
- Vitamin D Levels in Black Americans and the Association with Left Ventricular Remodeling and. (2022) (0)
- Abstract 18204: Generalizability Of The Paradigm-HF Trial For The Use Of Sacubitril/Valsartan In A Tertiary Care Outpatient Heart Failure Patient Population (2016) (0)
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply. (2022) (0)
- Evidence for an Association of Beta Blocker Dose with Outcome in Heart Failure: Insights from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2010) (0)
- Longitudinal changes in cardiac troponin and risk of heart failure among Black adults. (2022) (0)
- Abstract 23237: Improvement in Quality of Care for Atrial Fibrillation in Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) (2016) (0)
- Abstract 14348: Inotrope Use and Outcomes in Hospitalized Heart Failure: Impact of Etiology, Systolic Blood Pressure, and Cardiac Output _ Insights From ESCAPE (2013) (0)
- Abstract 13711: Incident Heart Failure Risk Stratification with Clinical Risk Factors, Natriuretic Peptides, and Echocardiography: The Cardiovascular Health Study (2011) (0)
- Heart Failure Prevention (2011) (0)
- Abstract 16921: Atrial Fibrillation is Associated with Significant Physical Function Decline in Older Adults (2014) (0)
- NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT (2023) (0)
- Abstract 1452: Systolic Blood Pressure and Heart Failure Risk in the Elderly: The Health, Aging, and Body Composition Study (2009) (0)
- Abstract 17390: Association of Arterial Stiffness With Risk of Heart Failure and its Subtypes Among Community-dwelling Participants of the HealthABC Study (2016) (0)
- Joint Associations of Obesity and Cigarette Smoking With Inflammation and Thrombosis (2021) (0)
- Contributing Authors (1999) (0)
- Safety and Effectiveness of an Individualized Risk Stratification Based Medication Intervention Strategy: The Intervene HF Study (2019) (0)
- Abstract 17027: Generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry (2020) (0)
- 331: Cardiac Index, Peak Exercise Oxygen Consumption, and Listing Priority for Cardiac Transplantation (2010) (0)
- Abstract 19094: Use of ACE Inhibitors or Angiotensin Receptor Blockers is Associated With a Significantly Lower Risk of 30-day All-cause and Heart Failure Readmissions and All-cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure Developing Acute Kidney Injury (2015) (0)
- Abstract 2307: Seattle Heart Failure Model Overestimates Time to Mortality in Patients Referred for Heart Transplantation (2007) (0)
- A Comparison of Self Care Behaviors and Outcomes in HF Patients with and without Diabetes (2008) (0)
- Abstract 21224: Health Literacy in Outpatients with Heart Failure: Determinants and Association with Outcomes (2010) (0)
- Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. (2022) (0)
- Abstract 9816: Placenta Characteristics in Women With Heart Disease and Possible Impact on Fetal Outcomes (2015) (0)
- Progression of Pulmonary Artery Systolic Pressures by Echocardiography among Ambulatory Patients without Pulmonary Hypertension at Baseline (2013) (0)
- Abstract P385: Cigarette Smoking and Incident Stroke in African Americans of the Jackson Heart Study (2019) (0)
- AbstractPeak exercise oxygen consumption and survival among elderly patients with heart failure (2004) (0)
- THE RELATIONSHIP BETWEEN BODY WEIGHT CHANGE DURING HOSPITALIZATION FOR ACUTE HEART FAILURE AND PATIENT CHARACTERISTICS, MARKERS OF CONGESTION, AND OUTCOMES: FINDINGS FROM ASCEND-HF (2016) (0)
- MINERALOCORTICOID RECEPTOR ANTAGONISTS IN DIABETIC PATIENTS HOSPITALIZED WITH HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Leadership in cardiology. (2017) (0)
- Digoxin and Outcomes in Patients with Advanced Heart Failure and Contemporary Optimal Treatment (2008) (0)
- Insufficient Reduction in Heart Rate during Hospitalization Despite Beta-Blocker Treatment in Acute Decompensated Heart Failure (2016) (0)
- Prescription Patterns of Guideline Directed Therapies And Clinical Outcomes In Patients With Heart Failure, Based on Human Immunodeficiency Virus Status (2020) (0)
- CRT-700.04 Impact of Discharge Home without Home Services on 30-Day Outcomes Following Transcatheter Aortic Valve Replacement with Contemporary Valves (2018) (0)
- Abstract 17237: Physical Inactivity, Mortality and Incident Coronary Heart Disease in Blacks: The Jackson Heart Study (2018) (0)
- Gender Differences in Risk of Neurologic Events during Support with Continuous Flow Left Ventricular Assist Device (LVAD) (2014) (0)
- Abstract 12916: Cost-Related Medication Non-Adherence in Nonelderly With Atherosclerotic Cardiovascular Disease in the United States, 2013-2016 (2018) (0)
- The Predictive Value of Left Atrial Volume in Patients Referred for Transplant Evaluation (2007) (0)
- Abstract 20782: Discharge Hospice Referral is Associated With Lower 30-Day All-Cause Readmission in Hospitalized Patients With Heart Failure: A Propensity-Matched Study of the Medicare-Linked OPTIMIZE-HF (2016) (0)
- Impact of Physician Type on Hospital Charges for DRG 127 (Heart Failure and Shock); Heart Failure Specialists Provide More Cost-effective Care (1998) (0)
- DOES FRAILTY MODULATE HEALTH STATUS IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION? (2022) (0)
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial. (2023) (0)
- Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT Trial. (2023) (0)
- Abstract 18350: Impact of Amount vs Duration of Smoking on Incident Heart Failure and Mortality Among Community-dwelling Older Adults: Need to Reassess the Role of Pack-years as a Tool to Estimate Smoking (2015) (0)
- CDC-WONDER Database Analysis of COVID-19 and Cardiovascular Disease-Related Mortality (2023) (0)
- Reply (0)
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. (2023) (0)
- 5 6 Developed in Collaboration With the American Academy of Family Physicians, American College 7 of Chest Physicians, Heart Rhythm Society and International Society for Heart and Lung (2013) (0)
- Gopal response to Arques (2010) (0)
- Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure. (2023) (0)
- Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. (2022) (0)
- Contributing Authors (1996) (0)
- Pragmatism in clinical trials: essential, not optional. (2022) (0)
- Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. (2023) (0)
- Hospital at Home as a Novel Care Strategy for Worsening Heart Failure. (2023) (0)
- The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease (2021) (0)
- Efficacy of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors for heart failure in black patients: a systematic review and meta‐analysis of randomized controlled trials (2023) (0)
- The Time for Preparation Is Now* (2022) (0)
- Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction. (2023) (0)
- Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause (2022) (0)
- vention with DES, stratified by different stages of retinopathy, are warranted. (2007) (0)
- Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. (2023) (0)
- PROGNOSTIC ROLE OF HEMOCONCENTRATION IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS OF THE EVEREST TRIAL (2013) (0)
- Abstract 14029: Cumulative Cigarette Smoking Exposure and Heart Failure Risk in Older Adults the Health, Aging, and Body Composition (Health ABC) Study (2011) (0)
- Routine Screening for AMR By C4d Immunohistochemical Staining Is of Low Clinical Utility and Associated With High False‐Positive Rates: A Single Center, 2 Year Analysis of 1518 Biopsies.: Abstract# 1375 (2014) (0)
- UTILIZATION RATES OF SGLT2 INHIBITORS AND THEIR FACILITY-LEVEL VARIATION AMONG PATIENTS WITH TYPE 2 DIABETES (T2DM), HEART FAILURE (HF) AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): INSIGHTS FROM THE DEPARTMENT OF VETERANS AFFAIRS (VA) (2023) (0)
- Reply: Ethnic diversity and immunological barriers in heart transplantation. (2014) (0)
- Abstract 19793: Relationship Between Self-care, Functional Health, and Health Resource Use in Adults With Congenital Heart Defects (2015) (0)
- ASSOCIATIONS OF DIABETES AND HYPERTENSION WITH LEFT VENTRICULAR MASS-THE JACKSON HEART STUDY (2020) (0)
- Improvements in Health Status Associated with Medication Adjustments in Outpatients with HFrEF: Insights from the CHAMP-HF Registry (2018) (0)
- A Novel Metabolomics Risk Score Associated with Sex-Sifferences in Heart Failure (2020) (0)
- Abstract 1638: Association between Cardiovascular Risk Profiles and the Presence and Extent of Different Types of Coronary Atherosclerotic Plaque as Detected by Multidetector Computed Tomography (2007) (0)
- Mid‐regional pro‐atrial natriuretic peptide for diagnosis of heart failure in non‐acute settings: biomarkers plus clinical sense make good sense (2019) (0)
- AMONG OLDER HEART FAILURE (HF) PATIENTS WITH IN-HOSPITAL ACUTE KIDNEY INJURY (AKI), AN IMPROVEMENT IN KIDNEY FUNCTION IS ASSOCIATED WITH A HIGHER RISK OF POST-DISCHARGE MORTALITY BUT NOT READMISSION (2017) (0)
- Abstract 1451: Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study (2009) (0)
- Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial (2022) (0)
- Abstract 252: Regional Variations in Access to Care Among U.S. Veterans With Cardiovascular Disease (2018) (0)
- A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study (2023) (0)
- Worsening Renal Function in a Patient with Acute Heart Failure and Volume Overload (2019) (0)
- Abstract P196: Hand Grip Strength, Gait Speed And Incident Heart Failure In Older Adults (2022) (0)
- Association between Sacubitril/Valsartan Initiation and Health Status Outcomes inHeart Failure with Reduced Ejection Fraction:Findings from the CHAMP-HF Registry (2018) (0)
- EFFECT OF PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY ON MORTALITY AND SUDDEN CARDIAC DEATH IN HEART FAILURE TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL (2023) (0)
- PREDICTION OF DIURETIC RESISTANCE IN PATIENTS WITH CHRONIC STABLE HEART FAILURE: THE BAN-ADHF RISK SCORE (2022) (0)
- Abstract 18743: Lack of Evidence of Higher 30-day All-cause Readmission Among Older African American (vs. White) Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
- THE IMPACT OF AGE ON THE OUTCOMES AFTER CAROTID ARTERY STENTING OR ENDARTERECTOMY IN PATIENTS WITH MODERATE OR SEVERE CHRONIC KIDNEY DISEASE (STAGE 3 AND 4): INSIGHTS OF THE HEALTHCARE COST AND UTILIZATION PROJECT’S NATIONAL INPATIENT SAMPLE (2016) (0)
- TRENDS IN UTILIZATION OF SURROGATE ENDPOINTS IN CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS: A SYSTEMATIC REVIEW (2016) (0)
- Abstract 10790: Association of Beta Blocker Dose with Outcome in Heart Failure is Not Altered by Age: Insights from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2010) (0)
- Abstract 15365: Real World Treatment Patterns of US Patients With Worsening Chronic Heart Failure: Evidence From Linked PINNACLE Registry and Claims Data (2017) (0)
- HEARTJNL225482 1304..1311 (0)
- Outcomes in Outpatients with Heart Failure with Preserved Ejection Fraction: Implications for Clinical Trials (2014) (0)
- Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial (2021) (0)
- Accepted Manuscript Characterization of Cardiac Injury During Acute Heart Failure and a Possible Target for Therapy (2014) (0)
- The hi-tech age of heart failure management. (2015) (0)
- Abstract 12797: Temporal Changes in Mortality Risk Post-Discharge After Hospitalization for Heart Failure (2014) (0)
- A world view of heart failure requiring hospitalization. Foreword. (2013) (0)
- Plasma Cystine and Nitrite Levels are Synergistic Determinants of Arterial Stiffness and Mortality in Heart Failure (2019) (0)
- Consensus Statement Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research (2013) (0)
- Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure (2022) (0)
- Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (0)
- Abstract 16058: Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial (2017) (0)
- Abstract 18743: Digoxin and Hospital Readmission in Older Patients With Heart Failure and Reduced Ejection Fraction Receiving Beta Blockers: A Propensity Matched Study of Medicare Linked OPTIMIZE HF (2017) (0)
- Pharmacotherapy for heart failure: the more we get to know, the more we need to know. Foreword. (2014) (0)
- Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis. (2022) (0)
- Abstract 18927: Systolic Blood Pressure (SBP) <130 mmHg and Outcomes in Patients With Heart Failure and Preserved Ejection (HFpEF) and Hypertension (HTN) (2017) (0)
- Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database. (2022) (0)
- Abstract 14987: Association of ECG Abnormalities and Incident Heart Failure Events (2012) (0)
- Sodium–glucose cotransporter 2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: time to deliver implementation (2022) (0)
- Abstract 428: DNA Methylation of ASC is Associated with Decreased ASC and IL-1β Expression in Heart Failure (2015) (0)
- L-LEUCINE: A NOVEL BIOMARKER THAT PREDICTS LOWER MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (2020) (0)
- SACUBITRIL-VALSARTAN FOLLOWING HOSPITAL DISCHARGE FOR HEART FAILURE (2020) (0)
- Regional variations in cardiovascular risk factors and access to care among US veterans with cardiovascular disease (2020) (0)
- Abstract 18108: Effects of a Heart Failure Family Caregiver Intervention on Caregiver Strain and Outcomes (2014) (0)
- Abstract 14841: Definitions of Stage D Heart Failure and Survival: Comparing INTERMACS Profiles, ESC Criteria, and Physician Assessment (2015) (0)
- Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ•’AHF trial (2019) (0)
- Abstract 17602: Dietary Sodium Intake and 10-Year Mortality in Older Adults: The Health, Aging, and Body Composition (Health ABC) Study (2012) (0)
- STALLED NATIONAL PROGRESS IN HEART FAILURE HOSPITALIZATIONS AMONG PATIENTS WITH DIABETES MELLITUS (2020) (0)
- 2 Circ Cardiovasc Qual Outcomes May 2013 Targets for Incentives and Ethical Implications Referring Providers (0)
- The Updated Heart Failure Guidelines: Time for a Refresh. (2022) (0)
- The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF (2015) (0)
- Association between resting and exercise hemodynamics with renal function in patients with heart failure and depressed ejection fraction (2003) (0)
- Atrial Natriuretic Peptide Mediates Reverse Cardiac Remodeling During Treatment with Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (2020) (0)
- Hemodynamic Correlates of Outcomes in Patients Hospitalized for Heart Failure (2009) (0)
- Validation of the Seattle Heart Failure Model in Patients Referred for Transplant Evaluation (2007) (0)
- Early Medical Management of Hospitalization for Heart Failure (HHF) (2015) (0)
- DCRM Multispecialty Recommendations in Patients with Heart Failure: For Special Issue on Cardio-Renal-Metabolism. (2022) (0)
- Global and Regional Left Ventricular Function Assessment with 64-Slice MDCT in Heart Failure Patients: A Comparative Study with Echocardiography (2006) (0)
- Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high‐risk heart failure patients (Confirm‐AF trial) (2022) (0)
- Review Article The Potential Role of Natriuretic PeptideeGuided Management for Patients Hospitalized for Heart Failure (2015) (0)
- Abstract 17584: Pulmonary Artery Systolic Pressure Independently Predicts All-Cause Mortality in Patients with Coronary Artery Disease Irrespective of a Diagnosis of Heart Failure (2014) (0)
- Lower Discharge Systolic Blood Pressure (SBP) and Poor Outcomes Among Hospitalized Patients With Heart Failure and Reduced Ejection Fraction (HFrEF) and Stable Admission-to Discharge SBP (2017) (0)
- The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction? (2022) (0)
- BIOMARKERS AND STRAIN ECHOCARDIOGRAPHY FOR THE DETECTION OF SUBCLINICAL CARDIOTOXICITY IN BREAST CANCER PATIENTS RECEIVING ANTHRACYCLINES (2023) (0)
- INTERLEUKIN-6 IS ASSOCIATED WITH, BUT DOES NOT INDEPENDENTLY PREDICT, MORTALITY IN ACUTE HEART FAILURE: AN ASCEND-HF SUBSTUDY (2015) (0)
- Health Literacy, Self-Reported Education and Outcomes among Heart Failure Outpatients (2010) (0)
- Elevated PVR Is Associated with Improved 6-Month Survival in Patients on Continuous Milrinone Infusion as Destination Therapy (2014) (0)
- Poor Medication Adherence Is Associated With Worse Health Status In Heart Failure With Reduced Ejection Fraction (2022) (0)
- Racial Variations in Outcomes with Diuretics in Advanced Heart Failure (2008) (0)
- Abstract 19127: Gamma glutamyltransferase and Risk of Incident Heart Failure (2014) (0)
- Left ventricular assist device implnatation is associated with improvement in renal function among patients with pre-implant renal inusfficiency (2005) (0)
- IMPACT OF HEART FAILURE HOSPITALIZATION ON GUIDELINE-DIRECTED MEDICAL THERAPY PRESCRIBING PATTERNS AMONG PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS FROM CHAMP-HF (2020) (0)
- IMPACT OF CHRONIC KIDNEY DISEASE ON MORTALITY IN ADULTS UNDERGOING BALLOON AORTIC VALVULOPLASTY (2017) (0)
- PRIOR HEART FAILURE HOSPITALIZATION AMONG PATIENTS HOSPITALIZED FOR WORSENING CHRONIC HEART FAILURE: FROM THE ASCEND-HF TRIAL (2018) (0)
- ADJUSTMENT OF GUIDELINE-DIRECTED MEDICAL THERAPY ONE YEAR POST-HEART FAILURE HOSPITALIZATION FALLS SHORT: INSIGHTS FROM THE CONNECT-HF TRIAL (2023) (0)
- Score-Based Versus Clinical Evaluation of Heart Failure Severity among Patients Listed for Heart Transplantation (2013) (0)
- Abstract P141: Association Of Obesity And Cigarette Smoking With Markers Of Inflammation And Thrombosis (2021) (0)
- Editorial Board (1982) (0)
- Cardiac Index, Maximal Oxygen Consumption, and Outcomes in Patients with Advanced Heart Failure (2009) (0)
- Abstract 12208: Mode of Death in Heart Failure With Preserved Ejection Fraction: A Systematic Review (2016) (0)
- HYPERKALEMIA AFTER HOSPITALIZATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: FINDINGS FROM THE ASTRONAUT TRIAL (2018) (0)
- Abstract 11478: Physical Activity and Biomarkers of Inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study (2019) (0)
- Pulmonary Function Testing Parameters at the Time of Listing and Outcomes in Patients Listed for Heart Transplantation (2010) (0)
- Baseline Cystatin C is Associated with Short-Term Adverse Events in Acute Heart Failure but Does Not Predict Treatment Effects with Nesiritide Therapy (2011) (0)
- Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice (2022) (0)
- Abstract 14928: Burden and Consequences of Medical Debt From Healthcare Bills Among Non-Elderly Adults With Atherosclerotic Cardiovascular Disease in the United States (2018) (0)
- RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITION IN HEART FAILURE WITH MID-RANGE EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2019) (0)
- Abstract 5910: Digoxin and Outcomes in Patients with Advanced Heart Failure on Contemporary Optimal Treatment (2008) (0)
- Abstract 17733: Pulmonary Artery Systolic Pressure by Echocardiography and Outcomes in Stable Outpatients with Heart Failure (2012) (0)
- High Sensitivity Troponin I in Acute Decompensated Heart Failure (2011) (0)
- Clinical Investigations Trends in Heart Failure Clinical Trials From 2001e2012 (2016) (0)
- Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan. (2023) (0)
- Lower hemoglobin is associated with reduced survival in unselected patients with heart failure: results from the study of anemia in a heart failure population (STAMINA-HFP) registry (2004) (0)
- Abstract 12817: Comparison of New York Heart Association Classification and Patient-reported Outcomes Among Heart Failure Patients in U.S. Clinical Practice: CHAMP-HF (2020) (0)
- Likelihood classification vs risk stratification in acute chest pain (2009) (0)
- STRONG-HF and Implementing Heart Failure Therapies: Godspeed … With Care. (2023) (0)
- Therapeutic Advances in Patients with Heart Failure with Reduced Ejection Fraction Who Have Had a Previous Worsening Heart Failure Event (2020) (0)
- Abstract 13809: Serial Paraoxonase-1-associated Serum Arylesterase Activity and Outcomes in Ambulatory Patients With Heart Failure (2015) (0)
- CRT-700.15 Impact of Severity of Renal Dysfunction on 30-Day Readmission Following Transcatheter Aortic Valve Replacement with Contemporary Valves (2018) (0)
- Prognostic value of the MAGGIC score, H2FPEF score and HFA-PEFF algorithm in patients with exertional dyspnea and the incremental value of exercise echocardiography. (2022) (0)
- Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES) (2014) (0)
- Abstract 20774: Discharge Heart Rate and Outcomes in Hospitalized Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) and Stable Admission-to-Discharge Heart Failure (2016) (0)
- Abstract 13480: Exercise Capacity and Risk for Heart Failure in Older Adults. The Health, Aging, and Body Composition Study (2011) (0)
- Abstract P225: Hyperhomocysteinemia Mediates the Association of Food Deserts With Recurrent Heart Failure Hospitalizations (2019) (0)
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. (2023) (0)
- Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials. (2023) (0)
- Pre-operative renal function and outcomes after left ventricular assist device implantation (2004) (0)
- Uptitrating vs Adding HFrEF Medications: Bring More Players to the Game. (2022) (0)
- JAMA Cardiology List of Peer Reviewers. (2017) (0)
- Abstract 834: Predictors of New-Onset Heart Failure in a Large Insured Population: A One Million Person-Years Follow-up Study (2009) (0)
- Abstract 13158: Hospitalization for De Novo versus Worsening Chronic Heart Failure: Insights From the ASCEND-HF Trial (2016) (0)
- The importance of forward flow and venous congestion in diuretic response in acute heart failure: Insights from the ESCAPE trial. (2023) (0)
- Left ventricular ejection fraction change and prognosis among heart failure patients treated with beta-blockers (2003) (0)
- Abstract 9698: Cigarette Smoking and Incident Coronary Heart Disease in African Americans: The Jackson Heart Study (2019) (0)
- EMERGENCY DEPARTMENT VISITS VERSUS HOSPITAL READMISSION AMONG PATIENTS WITH HEART FAILURE: FINDINGS FROM ASCEND-HF (2021) (0)
- EFFECT OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY ON LONG TERM SURVIVAL IN AFRICAN AMERICANS (AA) WITH HEART FAILURE (HF) (2012) (0)
- Abstract 1450: Abnormal Lung Function and Risk for Heart Failure in the Elderly: The Health, Aging, and Body Composition Study (2009) (0)
- Patiromer For The Management Of Hyperkalemia In Patients Receiving Renin-Angiotensin-Aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction Has No Difference By Sex: Results From The Diamond Trial (2023) (0)
- Abstract 18263: Poor Handgrip Strength and Outcomes in Heart Failure. The Atlanta Cardiomyopathy Consortium (2013) (0)
- The Enabling Potential of Device Therapy for Heart Failure. (2022) (0)
- Abstract 18094: Multimorbidity and 30-Day All-Cause Readmission Among Hospitalized Medicare Beneficiaries With Heart Failure (2013) (0)
- Aetiology of heart failure is in the eye of the beholder: does it even matter? (2021) (0)
- Abstract 16298: Importance of Event vs. Nonevent Weighting and Baseline Risk Assessment in Risk Reclassification for Heart Failure: The Cardiovascular Health Study (2011) (0)
- The Time is Now for SGLT2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. (2020) (0)
- Self-care in Persons with Heart Failure and Diabetes Differs by Comorbidity Clusters (2020) (0)
- CRT-700.34 Impact of Gender on Mortality in Adults Undergoing Transcatheter or Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis (2018) (0)
- DIFFERENCES IN THERAPY AND DECONGESTION BETWEEN MEN AND WOMEN HOSPITALIZED FOR ACUTE HEART FAILURE: FINDINGS FROM ASCEND-HF (2020) (0)
- Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials (2022) (0)
- A Practical Approach to Managing Heart Failure in Type 2 Diabetes Mellitus (2019) (0)
- P4368Characteristics and treatment of worsening chronic heart failure: real world evidence from linked PINNACLE Registry and claims data (2017) (0)
- Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN‐HF Registry (2021) (0)
- Abstract 5880: Serum Resistin Concentrations and Risk of New Onset Heart Failure in the Elderly (2008) (0)
- INCREASED LEVELS OF SOLUBLE FMS-LIKE TYROSINE KINASE 1 (SFLT-1) ARE ASSOCIATED WITH WORSE OUTCOMES IN OUTPATIENTS WITH HEART FAILURE (2012) (0)
- 306: Effect of LVAD on renal function and other outcomes in patients with impaired renal function (2006) (0)
- Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart Association Get With The Guidelines - Heart Failure Registry (2015) (0)
- Metabolic syndrome predicts adverse cardiovascular risk among the elderly (2005) (0)
- 144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies (2020) (0)
- How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines? (2022) (0)
- A two decade perspective on acute heart failure research：part one (2017) (0)
- CRT-100.05 The Impact of Initial Left Ventricular End Diastolic Pressure on the Incidence of Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (2018) (0)
- Pulmonary Function Testing and Prognosis in Heart Failure Patients Listed for Heart Transplantation (2014) (0)
- METHODS: Serial section of 25 proteinuric kidneys from patients with Lupus nephri- tis, IgA Nephropathy, Membranous Glomerulopathy and Minimal Change Disease (2018) (0)
- Worsening Cardiovascular Disease Epidemiology in the United States (2022) (0)
- Cost Effectiveness of an Integrated Self Care Intervention for Persons with Heart Failure and Diabetes (2014) (0)
- Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry (2018) (0)
- 184: Utility of the Seattle Heart Failure Model in Patients with Advanced Heart Failure Treated with Implantable Cardioverter Defibrillators and/or Biventricular Pacemakers (2008) (0)
- Abstract 1115: Medication Complexity in Heart Failure (2009) (0)
- Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis. (2023) (0)
- Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure. (2022) (0)
- Digoxin Is an Independent Predictor of Outcomes in Contemporary Advanced Heart Failure Patients in Addition to the Seattle Heart Failure Model (2008) (0)
- Biomarkers and Cancer Therapy-Related Cardiac Dysfunction (2016) (0)
- EFFECT OF SGLT2 INHIBITORS ON LEFT VENTRICULAR REMODELING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2022) (0)
- Abstract 17143: Shorter Length of Stay is Associated With Significantly Lower 30-day All-cause Readmission and 30-day All-cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
- OUTCOMES IN OUTPATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (2015) (0)
- ASSOCIATION BETWEEN ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITION, CARDIOVASCULAR BIOMARKERS AND CARDIAC REMODELING IN HEART FAILURE WITH REDUCED EJECTION FRACTION (2021) (0)
- and Mihai Gheorghiade Therapies Contemporary Drug Development in Heart Failure : Call for Hemodynamically Neutral (0)
- Abstract 18977: Improving Self-care for Diabetes Affects Heart Failure Outcomes in Persons With Heart Failure and Concomitant Diabetes (2017) (0)
- Management of Heart Failure with Reduced Ejection Fraction. (2023) (0)
- Sex Disparity Among Canadian Cardiologists in Academic Medicine: Differences in Scholarly Productivity and Academic Rank (2021) (0)
- Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology (2017) (0)
- Abstract P027: Fasting Glucose And Risk Of Heart Failure (2014) (0)
- Abstract 10119: Cardio-respiratory Fitness and Incident Heart Failure (2013) (0)
- Abstract 11673: Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study (2012) (0)
- Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients with Type 2 Diabetes: Fidelity Analyses (2022) (0)
- Abstract 18059: Clinical Profile and Prognostic Significance of Post-Discharge Hemodilution Among Patients Hospitalized for Heart Failure: Insights From the EVEREST Trial (2017) (0)
- Abstract 17511: Discharge Initiation of Beta Blocker Therapy is Associated With Significantly Lower 30 Day Mortality Without Associated Increase in 30 Day All Cause Readmission in Hospitalized Older Patients With Heart Failure and Reduced Ejection Fraction (2013) (0)
- Duration of Heart Failure, In-hospital Clinical Trajectory, and Post-discharge Outcomes Among Patients Hospitalized for Heart Failure. (2022) (0)
- Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. (2022) (0)
- Get a move on heart failure. (2015) (0)
- INITIATION OF LOOP DIURETIC THERAPY IS ASSOCIATED WITH A LOWER RISK OF 30-DAY ALL-CAUSE READMISSION IN PATIENTS WITH HEART FAILURE NOT RECEIVING DIURETICS PRIOR TO HOSPITALIZATION (2018) (0)
- Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience (2014) (0)
- THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2020) (0)
- HEALTH RELATED QUALITY OF LIFE AND FUNCTIONAL CLASS ARE INDEPENDENTLY RELATED TO OUTCOMES IN UNSELECTED OUTPATIENTS WITH HEART FAILURE: INSIGHTS FROM THE STUDY OF ANEMIA IN A HEART FAILURE POPULATION (STAMINA-HFP) REGISTRY (2010) (0)
- Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. (2023) (0)
- Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials (2021) (0)
- USE OF HYDRALAZINE/NITRATE, ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR AND OTHER GUIDELINE-DIRECTED MEDICAL THERAPIES AMONGST AFRICAN AMERICANS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM CHAMP-HF (2019) (0)
- Wait List Mortality Is Higher for Female Heart Transplant Candidates (2013) (0)
- Abstract 17212: 30-day All-cause Readmission is Associated With a Significantly Higher Subsequent All-cause Mortality and Costly Readmissions Among Older Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
- Abstract 3707: Dopamine Prevents Worsening of Renal Function and Hypokalemia During Hospitalization for Acute Decompensated Heart Failure (2009) (0)
- Traditional and Novel Markers of Renal Function and Outcomes in Outpatients with Heart Failure: The Atlanta Cardiomyopathy Consortium (TACC) (2012) (0)
- Abstract 17428: Discharge Prescriptions for Spironolactone and 30-day All-cause Readmission in Hospitalized Medicare Beneficiaries With Heart Failure, LVEF Less Than 45% and eGFR Less Than 45 (2013) (0)
- Faculty Opinions recommendation of Predictors of outcome in patients with suspected myocarditis. (2008) (0)
- 1012-126 Contemporary dosing of angiotensin converting enzyme inhibitors and beta blockers in chronic heart failure: Report from the STAMINA:HFP (study of anemia in a heart failure population) registry (2004) (0)
- Faculty Opinions recommendation of Coenzyme Q10: an independent predictor of mortality in chronic heart failure. (2008) (0)
- Abstract 10426: Worse Clinical Outcomes in Patients with Acute Coronary Syndrome and Prior or New Onset Heart Failure: Insights from 47,474 Patients in a Pooled Analysis of Randomized Clinical Trials (2021) (0)
- Resting and exercise hemodynamics among heart failure patients treated with and without beta-blockers (2003) (0)
- Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-black Patients With Heart Failure and Reduced Ejection Fraction (HFREF) (2017) (0)
- CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL (2021) (0)
- 338: Utility of the Seattle Heart Failure Model in Medically Treated Patients with Advanced Heart Failure (2008) (0)
- High Intensity Interval Training Versus Moderate Continuous Training in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. (2023) (0)
- Impact of Sociodemographic and Clinical Risk Factors on Hospitalisation Rates Among Ambulatory Patients with Heart Failure and Preserved Ejection Fraction (2015) (0)
- Epidemiology of Heart Failure (2020) (0)
- The inadequacy of cardiovascular safety reporting in breast cancer clinical trials. (2020) (0)
- Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors (2019) (0)
- Vericiguat and health status outcomes in heart failure with reduced ejection fraction: insights from the VICTORIA trial (2021) (0)
- Interaction of Natriuretic Peptide Levels and Ejection Fraction on Outcomes with Dapagliflozin and Empagliflozin in Heart Failure. (2023) (0)
- SECONDHAND SMOKE IS LINKED TO HIGHER RISK OF NON-CARDIOVASCULAR MORTALITY BUT NOT OF CARDIOVASCULAR MORTALITY IN COMMUNITY-DWELLING OLDER ADULTS: FINDINGS FROM CARDIOVASCULAR HEALTH STUDY (CHS) (2018) (0)
- Cangrelor Use in the Treatment of Left Ventricular Assist Device Thrombosis : A Case Report (0)
- Risk Factors for Heart Failure Progression and Outcomes (2006) (0)
- Abstract 13202: QI-Focused Interventions Addressing Shared Decision-Making Practices for Patients with Heart Failure (2018) (0)
- Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study. (2023) (0)
- Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association ( HFA ) of the ESC (2023) (0)
- CHRONIC ALPHA BLOCKER USE AND OUTCOMES IN OLDER MALE MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2017) (0)
- Abstract 18870: Adjudicated versus “Administrative” Heart Failure With Preserved Ejection Fraction (2014) (0)
- Pre-transplant reversible pulmonary hypertension predicts a higher risk for mortality post-transplant (2002) (0)
- Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors. (2019) (0)
- Examining Whether a Self-Care Program Reduces Healthcare Use and Improves Health among Patients with Acute Heart Failure -- The GUIDED HF Study (2021) (0)
- Abstract 13641: Serum Vitamin D3 Levels, Left Ventricular Structure and Incident Hospitalization for Heart Failure With Preserved Ejection Fraction in African Americans: The Jackson Heart Study (2020) (0)
- Use Of Sacubitril-valsartan And Associated Outcomes By Race And Ethnicity In Patients With Heart Failure With Reduced Ejection Fraction: Data From Champ-HF (2022) (0)
- IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)? (2012) (0)
- CLASSIFICATION AND IMPLICATIONS OF HEART FAILURE EVENTS FROM THE VICTORIA TRIAL (2022) (0)
- Abstract 10413: Clinical Outcomes with Metformin and Sulfonylurea Initiation Among Patients with Heart Failure and Diabetes: From Get with the Guidelines-Heart Failure (2021) (0)
- Abstract 17601: Left Atrial function Assessed by Cardiac Magnetic Resonance Imaging in Patients With Heart Failure With Preserved and Reduced Left Ventricle Ejection Fraction With and Without Symptoms (2015) (0)
- Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure (2021) (0)
- Abstract 3088: Association between Coronary Plaque Burden as Measured by Multidetector Computed Tomography and Inflammatory Biomarkers in Patients with Acute Chest Pain (2007) (0)
- Incident Coronary Revascularization and Subsequent Mortality in Systolic and Diastolic Heart Failure: A Propensity-Matched Study (2008) (0)
- Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. (2023) (0)
- NON-INFERIORITY DESIGNS OVER THE LAST DECADE OF CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS (2016) (0)
- Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion (2021) (0)
- P3522Vagus nerve stimulation for chronic heart failure: differences in therapy delivery and clinical efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (0)
- Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). (2020) (0)
- Abstract 17709: Cellular Aging as Reflected by Leukocyte Telomere Length and Incident Heart Failure Risk in Older Adults (2012) (0)
- Title: Acute Dyspnea and Decompensated Heart Failure Authors (2018) (0)
- Abstract 16681: Effect of ZS-9 Treatment for Hyperkalemia in Patients With Heart Failure Receiving Maximal, Submaximal or no Renin-angiotensin-aldosterone-system Inhibitors: Pooled Analysis From Two Phase III Trials (2016) (0)
- The Role of Renal Function Markers on the Discriminative Properties of the Seattle Heart Failure Model in Patients with Advanced Heart Failure (2008) (0)
- Abstract 12557: INTERMACS Profiles and Clinical Outcomes Among Ambulatory Patients With Systolic Heart Failure (2015) (0)
- Standardizing the standard: reporting health status in clinical trials (2021) (0)
- Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial (2022) (0)
- Abstract 15740: Effects of an Integrated Self-Care Intervention on Frailty Risk in Persons With Heart Failure and Type 2 Diabetes Mellitus (2014) (0)
- EFFECT OF SGLT2 INHIBITORS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS (2023) (0)
- EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL (2022) (0)
- Lack of Racial Variations in the Natural History of Chronic Heart Failure: A Propensity-Matched Study (2007) (0)
- TRENDS IN PREVALENCE OF HEART FAILURE IN CANCER: INSIGHTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (2023) (0)
- Contemporary Reviews in Cardiovascular Medicine Hydralazine and Isosorbide Dinitrate in Heart Failure Historical Perspective, Mechanisms, and Future Directions (2011) (0)
- DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia (2022) (0)
- Outpatient Continuous Inotropic Infusion for End Stage Heart Failure Patients Who Are Not Candidates for Cardiac Transplantation: Clinical, Hemodynamics, and Outcomes Profile (2003) (0)
- Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America. (2023) (0)
- Cherishing the life and legacy of Mihai Gheorghiade. (2017) (0)
- Abstract 255: The Development of an Observational Registry of Treatment Patterns in US Heart Failure Patients with Reduced Ejection Fraction (HFrEF) (2016) (0)
- Abstract 14230: Integration of Vascular Phenotyping With Metabolomic Profiling in Black Subjects With Heart Failure With Reduced Ejection Fraction (2020) (0)
- INFLUENCE OF URIC ACID LEVEL IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Admission Electrocardiogram Diagnosed Atrial Fibrillation is Independently Associated with 30-Day All-Cause Readmission in Older Medicare Beneficiaries Hospitalized for Heart Failure (2016) (0)
- Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post–hospital discharge period (2023) (0)
- Clinical and Research Considerations for Patients with Hypertensive Acute Heart Failure (2016) (0)
- Patients' Reporting Versus Electronic Health Record Documentation of Comorbidities among Heart Failure Patients (2010) (0)
- Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators (2021) (0)
- Abstract 16917: Unique Small Molecule Metabolites Are Associated With Racial Differences In Heart Failure Death And Hospitalization (2016) (0)
- Abstract 20967: Decreased Arylesterase Activity is Associated with Adverse Outcomes in Outpatients with Heart Failure (2010) (0)
- THE RELATIONSHIP BETWEEN BIOMARKERS OF INFLAMMATION AND LEFT VENTRICULAR STRUCTURE AND FUNCTION (2021) (0)
- PROGNOSTIC VALUE OF BASELINE AND CHANGES IN CIRCULATING SOLUBLE ST2 LEVELS AND THE EFFECTS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE (2015) (0)
- Barriers to Clinical Trial Efficiency: The Heart Failure Collaboratory Industry Experience (2019) (0)
- Abstract 15401: Hypertensive Diseases in Pregnancy and Renal Function Later in Life: Insights From the Genetic Epidemiology Network of Arteriopathy Study (2019) (0)
- Barriers to Clinical Trial Efficiency and Patient Access: The Heart Failure Collaboratory Industry Survey (2020) (0)
- THE EFFECT OF SGLT2 INHIBITORS ON HEART FAILURE OUTCOMES ACROSS DIFFERENT DISEASE STATES: A SYSTEMATIC REVIEW AND META-ANALYSIS (2022) (0)
- Gender, digoxin use and heart failure outcomes (2003) (0)
- A SCORE COMPRISED OF NOVEL METABOLITES RELATED TO MYOCARDIAL ENERGETICS IS ASSOCIATED WITH SEX DISPARITIES IN HEART FAILURE OUTCOMES (2019) (0)
- The Influence of Cardiopulmonary Exercise Testing and Renal Function on the Predictive Capability of the Seattle Heart Failure Model (2007) (0)
- Vericiguat for the treatment of heart failure with reduced ejection fraction (2023) (0)
- Depression Symptoms Evaluated by the PHQ-9 Instrument in Outpatients With Heart Failure in the Atlanta Cardiomyopathy Consortium (TACC) Study: Association With Health Care Resource Utilization and Quality of Life (2012) (0)
- The Syndrome of Heart Failure With Preserved Systolic Function. (2017) (0)
- 345: MULTIDRUG RESISTANT ORGANISM INFECTIONS IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES (2012) (0)
- Abstract 18053: Six Minute Walk Test and Outcomes in Stable Outpatients with Heart Failure: The Atlanta Cardiomyopathy Consortium (2012) (0)
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials (2018) (0)
- Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in hf and Reduced Ejection Fraction (HFrEF) (2017) (0)
- TEMPORAL TRENDS IN SEVERITY IN CLINICAL RISK PROFILES AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE (2020) (0)
- Abstract 20721: Death Despite Enalapril Therapy vs. Survival Despite Placebo in the Studies of Left Ventricular Dysfunction (SOLVD) Trial: Insights into the Role of Traditional Risk Factors for Mortality in Heart Failure and Reduced Ejection Fraction (HFrEF) (2016) (0)
- The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. (2013) (0)
- Preoperative Echocardiography Predicts Right Ventricular Failure After Implantation of Left Ventricular Assist Devices: Interim Results from a Prospective Cohort Study (2014) (0)
- Impact of diabetes on outcomes after left ventricular assist device placement (2004) (0)
- Abstract 20752: Clinical Effectiveness of Digoxin in Hospitalized Older Patients With Heart Failure and Preserved Ejection Fraction: A Propensity-Matched Study of Medicare-Linked OPTIMIZE-HF (2016) (0)
- Patients With Type 2 Diabetes Are More Resistant To Diuresis And Have Worse Acute Heart Failure Outcomes: Findings From ASCEND-HF (2023) (0)
- Current Smoking and a “Non-Paradoxical” Association with Mortality among Community-Dwelling Older Heart Failure Patients: Findings From the Cardiovascular Health Study (2016) (0)
- CLINICAL EFFECTIVENESS OF SPIRONOLACTONE IN HOSPITALIZED OLDER ELIGIBLE (EF LESS THAN OR EQUAL TO 35% AND EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M2) PATIENTS WITH HEART FAILURE (2017) (0)
- Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial (2017) (0)
- Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME (2020) (0)
- SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Racial Variations in the Incidence and Outcomes of Stroke in Chronic Heart Failure Patients with Normal Sinus Rhythm (2008) (0)
- Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure with Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. (2023) (0)
- ASC Methylation and Expression are Associated with Depressive Symptoms, Anxiety, and Quality of Life in Heart Failure (2015) (0)
- Abstract 13897: Decreased Diuretic Efficiency Rather Than Total Diuretic Dose is Associated With Reduced Survival Following Heart Failure Hospitalization (2014) (0)
- Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-Analysis. (2023) (0)
- Response to Letter Regarding Article, “Coronary Multidetector Computed Tomography in the Assessment of Patients With Acute Chest Pain” (2007) (0)
- Clinical performance and quality measures for heart failure management in China: the China‐Heart Failure registry study (2022) (0)
- C-REACTIVE PROTEIN IN ACUTE DECOMPENSATED HEART FAILURE: INSIGHTS FROM ASCEND-HF (2013) (0)
- The Renal Effects of Low-Dose Dopamine Infusion in Elderly Patients Hospitalized for Acute Decompensated Heart Failure (2010) (0)
- Influence of age on outcomes after left ventricular assist device placement (2004) (0)
- Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. (2021) (0)
- Abstract 14073: Trajectory of Congestion Metrics by Ejection Fraction in Acute Heart Failure - Findings From the Heart Failure Network (2016) (0)
- Predicting Risk among Patients Listed for Heart Transplantation: Is It the Same as a General Heart Failure Population? (2009) (0)
- Abstract 14450: Association of Trajectory of High Sensitivity C-reactive Protein and Incident Heart Failure in African Americans: The Jackson Heart Study (2020) (0)
- Prevalence And Excess Risk Of Hospitalization In Heart Failure With Reduced Ejection Fraction (2023) (0)
- Reporting and Definition of Kidney Death in Heart Failure Clinical Trials. (2022) (0)
- Potential Global Impact of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure. (2023) (0)
- Abstract 2624: An Analysis of CT Angiographic Patterns in Patients With vs. Without Acute Coronary Syndromes Presenting to the Emergency Department With Acute Chest Pain (2006) (0)
- Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME (2020) (0)
- Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States (2018) (0)
- Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction (2022) (0)
- Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure (2022) (0)
- HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF (2017) (0)
- POST-DISCHARGE MORTALITY AND READMISSION IN HEART FAILURE PATIENTS WITH PRESERVED, BORDERLINE, AND REDUCED LEFT VENTRICULAR EJECTION FRACTION (2014) (0)
- Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. (2023) (0)
- Response to Letter Regarding Article, “Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspectives, Mechanisms, and Future Directions” (2011) (0)
- DISCHARGE HOME HEALTH REFERRAL IS ASSOCIATED WITH HIGHER POST-DISCHARGE 30-DAY ALL-CAUSE READMISSION AND ALL-CAUSE MORTALITY AMONG OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2016) (0)
- Foreword. The Winning Team in Heart Failure: Dimensionality of Care Redesign. (2015) (0)
- TIME OF PRESENTATION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE (CLINICAL CHARACTERISTICS, INITIAL THERAPIES AND OUTCOMES): INSIGHTS FROM ASCEND-HF (2017) (0)
- Mihai Gheorghiade, MD-Life and Concepts. (2018) (0)
- The Contribution of Thoracic Radiation Dose Volumes to Subsequent Development of Cardiovascular Disease in Cancer Survivors (2021) (0)
- ORTHOPNEA OR PAROXYSMAL NOCTURNAL DYSPNEA IN OLDER ADULTS WITHOUT PREVALENT HEART FAILURE IS A PREDICTOR, BUT NOT AN INDEPENDENT RISK FACTOR FOR INCIDENT HEART FAILURE: INSIGHTS FROM THE CARDIOVASCULAR HEALTH STUDY (2017) (0)
- Palliative care and cardiovascular Disease and Stroke a Policy Statement From the american Heart association / american Stroke association aHa (2016) (0)
- Assessing health status after discharge for decompensated heart failure: a patient‐centred priority (2022) (0)
- 301 - The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF (2017) (0)
- Abstract 139: Comparison of Access to Care and Quality of Care in Veterans versus Non-veterans With Cardiovascular Disease (2017) (0)
- Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial (2022) (0)
- INFLUENCE OF CLINICAL TRIAL SITE ENROLLMENT ON PATIENT CHARACTERISTICS, PROTOCOL COMPLETION, AND ENDPOINTS: INSIGHTS FROM THE ASCEND-HF TRIAL (2016) (0)
- DECONGESTION, QUALITY OF LIFE, AND CLINICAL OUTCOMES AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED VERSUS PRESERVED EJECTION FRACTION (2022) (0)
- [OP.1B.10] RISK SCORE FOR INCIDENT HEART FAILURE: A SUBJECT-LEVEL META-ANALYSIS FROM THE HEART ‘OMICS’ IN AGEING (HOMAGE) DATABASE (2016) (0)
- Heart Failure Specific Versus All-Cause Endpoints in Heart Failure Clinical Trials. (2022) (0)
- Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus (2018) (0)
- SYSTEMATIC REVIEW OF PREVALENT AND INCIDENT HEART FAILURE IN CARDIOVASCULAR OUTCOME TRIALS OF PATIENTS WITH TYPE 2 DIABETES (2018) (0)
- Effects of an Exercise Intervention on ASC Methylation and IL-1 Cytokines in Persons with Heart Failure (2016) (0)
- “Administrative” Versus Adjudicated Heart Failure With Preserved Ejection Fraction (2014) (0)
- P2482Sex-based differences in cardioprotective role of SGLT-2 inhibitors in patients with type 2 diabetes mellitus (2019) (0)
- Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction. (2022) (0)
- Discovery and validation of a new biomarker for heart failure diagnostic (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Javed Butler?
Javed Butler is affiliated with the following schools:
- University of Mississippi
- Emory University
- Stony Brook University
- Mississippi State University
- University of Verona
- University of Mississippi Medical Center School of Dentistry
- University of Glasgow
- Columbia University
- Baylor University
- University of Erlangen–Nuremberg
- Vanderbilt University
- Hannover Medical School
- Stanford University
- RWTH Aachen University
- University of Pittsburgh
